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THE HITCHHIKER’S GUIDE TO KETAMINE-INDUCED CYSTITIS 
NICOLAS ANTHONY SIEGELMAN 
ABSTRACT 
 Ketamine, widely used as an anesthetic since the 1970s, recently gained 
U.S. Food and Drug Administration (FDA) approval for treatment-resistant 
depression as a nasal spray. The use of off-label IV ketamine for pain relief, 
depression, and suicidal ideation has yielded promising results, but the 
consequences of long-term ketamine treatment have not received adequate 
attention. The dramatic, irreversible changes to the bladder seen in ketamine 
abusers and animal models should raise red flags, but the urgent need for effective 
depression medications prompted expedited FDA approval. Therefore, it is of the 
upmost importance to understand the deleterious effect of ketamine on the bladder 
and potentially other organ systems before a severely vulnerable patient 
population is exposed to dosages of ketamine that have yet to be examined for 
their long-term safety. Through an evaluation of current research, a two-pronged 
mechanism of ketamine-induced cystitis, involving nerve hypertrophy and 
incomplete apoptosis, was elucidated and may serve as a valuable guide for 
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MAJOR DEPRESSIVE DISORDER 
Major depressive disorder (MDD) is a disabling condition that affected over 
320 million people world-wide in 2015 and has a prevalence that rose by 18.4% 
from 2005-2015 with no sign of slowing down.1 The Diagnostic and Statistical 
Manual of Mental Disorders (DSM-V) characterizes MDD through the presence of 
at least five diagnostic symptoms, one of which is either depressed mood or 
anhedonia, all existing during the same 2-week period and representing a change 
from baseline functioning. Identifying symptoms include: persistently depressed 
mood, diminished interest or pleasure in activities, significant weight loss or gain 
without intention, insomnia/hypersomnia, psychomotor disturbances, fatigue, 
inappropriate guilt/worthlessness, concentration issues, or thoughts of 
death/suicidal ideation.2 A leading cause of disability worldwide, MDD also 
represents a significant portion of U.S. healthcare costs, both direct and indirect. 
Half of all MDD patients experience a chronic or recurrent course that requires 
long-term treatment.3 As seen in Figure 1, MDD often exhibits a neuro-progressive 
course with increasing severity and reduced therapeutic response that leads to 
additional medications and increasing rates of hospitalization.4 In 2013, depressive 
disorders ranked as the sixth most expensive health condition overall behind 
diabetes mellitus, ischemic heart disease, low back and neck pain, hypertension, 




accounting for social and individual costs/losses, depressive disorders, particularly 
MDD, continue to approach an epidemic status that is inflamed by increasing rates 
of suicide globally and shockingly low remission and response rates. The Centers 
for Disease Control (CDC) reported a 3% increase in suicide rate across the total 
US population from 2005 to 2017 as suicide became the 10th leading cause of 
mortality in the United States. Increasing prevalence of depression and rates of 
suicide places immense pressure on the available armamentarium of psychiatrists 
and therapists to elicit not only a therapeutic effect but also one of an immediate 
and sustainable nature. 
 
Figure 1. Neuro-progressive course of MDD.  Despite achieving therapeutic 
response and potential remission, a majority of MDD patients experience relapse and 
recurrence. Each successive episode is characterized by increasing symptom severity 
and treatment duration, while the length of response winnows away. Upon reaching the 
chronic stage, most patients have exhausted preliminary treatment strategies and have 
developed resistance as their risk of hospitalization and associated health costs skyrocket. 
MDD = major depressive disorder. Figure taken from Ref. 4 (Sibille & French, 2013). 
 
The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) 
trial painted a bleak picture for depression outcomes, as only 50% of patients 




antidepressants. Of that 50%, only 30% of participants reached remission despite 
exhausting four escalating levels of treatment that included switching/additional 
medications, cognitive behavioral therapy, and lithium.6 Even with significant 
sample losses due to attrition, a startling 70% did not achieve remission, with a 
significant percentage not responding to any treatment level.7 The losses from 
attrition primarily resulted from intolerable side effects as medications were added, 
removed, or switched in a desperate chase of patient responses. A follow-up study 
of patients who achieved “remission” in the STAR*D indicated that greater than 
90% maintained at least one residual depressive symptom. Taken alone, the 
outlook appears quite bleak for MDD patients, particularly as many fail to seek 
treatment, suffer from comorbidities, and are often seen under urgent conditions 
given the emergent nature of severe depressive episodes. These aspects of MDD 
highlight the need for an immediate, generalizable, and cost-effective intervention. 
TREATMENT OPTIONS 
 Treatment options for MDD vary based upon setting and modality. The 
setting, either in-patient or out-patient, is a decision reached by care providers, the 
patient, and family members (if applicable) that depends on the level of care and 
observation the patient requires. In-patient treatment, or hospitalization, can be 
voluntary or involuntary, contingent on patient consent capacity/competence and 
expressed/suspected intention of self-harm or harm to others. The types of therapy 




response. The three modalities of therapy are pharmacotherapy, psychotherapy, 
and electroconvulsive therapy.  
Pharmacotherapy 
Pharmacotherapy involves multiple medication categories including 
antidepressants, stimulants, anti-psychotics, mood stabilizers, anxiolytics, and 
sometimes thyroid medication (primarily triiodothyronine). Typical first-line 
antidepressants are listed in Table 1 along with dosing and associated side effects. 
Most antidepressants are grouped by mechanism of action such as selective-
serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake 
inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase 
inhibitors (MAOIs). All antidepressants are nearly equal in their effectiveness and 
require 4-8 weeks of consistent treatment to elicit an effect. Differences in 





Table 1. Typical First-Line Antidepressants: Dosage, Metabolism, and Side Effects 
 
This table summarizes the dosage, metabolism, side effects, and toxicity of twelve 
common antidepressants. HTN = hypertension; SNRI = serotonin norepinephrine 
reuptake inhibitors; SSRIs = selective serotonin reuptake inhibitors. Table taken from Ref. 
8 (McKean et al., 2017). 
 
TCAs include imipramine, amitriptyline, doxepin, and nortriptyline and work 
by blocking the reuptake of both norepinephrine (NE) and serotonin (5-HT), 
increasing its synaptic availability. In addition to depression, TCAs can be used to 
treat enuresis, obsessive-compulsive disorder (OCD), and fibromyalgia. TCAs 
function as mild anticholinergics resulting in tachycardia and urinary retention in 
some patients. TCAs also exert a mild antagonism of alpha-adrenergic receptors 
resulting in sedation. TCAs can lower seizure threshold and produce significant 
toxic side effects such as coma, convulsions, and arrhythmias, and they are lethal 
during overdose. As a result, TCAs are rarely used as first-line anti-depressants, 
particularly in patients with suicidal ideation. TCAs produce wide-spread side 




These side effects result from mild antihistamine, antiadrenergic, and 
antimuscarinic properties.  
 The efficacy of MAOIs lends credence to the monoamine theory of 
depression, which states that depression results from decreased or imbalanced 
levels of amine neurotransmitters: dopamine, 5-HT, tyramine, and epinephrine. 
MAOI-As preferentially deactivate serotonin degradation, whereas MAOI-Bs 
preferentially inhibit the degradation of NE and epinephrine (E). Both classes of 
MAOIs act non-specifically on tyramine and dopamine. MAOIs attempt to stabilize 
and increase the availability of amine neurotransmitters by reducing the activity of 
monoamine oxidase, thus decreasing the degradation of necessary amines. 
MAOIs are often used in cases of treatment-resistant depression and atypical 
depression, as well as anxiety and hypochondriasis. Major side effects of MAOIs 
include hypertensive crisis, which can be lethal, and overstimulation of the central 
nervous system (CNS). Hypertensive crisis results from excess tyramine levels 
and is typically elicited by MAOI users ingesting a tyramine-rich diet or 
sympathomimetics. Given the presence of tyramine in a variety favorite foodstuffs, 
many patients struggle to adhere to MAOI treatment. Minor side effects include 
orthostatic hypotension, sexual dysfunction, drowsiness, dry mouth, sleep 
dysfunction, and weight gain. MAOIs include phenelzine, tranylcypromine, 
isocarboxazid, and selegiline and are not typically used as first-line 
antidepressants. These medications have tolerability and safety issues compared 




depression. Because of the increased risk of 5-HT toxicity syndrome, MAOIs are 
contraindicated in patients currently on a medication that augments serotonin 
levels.  
 SSRIs exert their antidepressant effect by selectively decreasing 5-HT at 
the pre-synaptic neuron by preventing its reuptake, resulting in amplified synaptic 
levels and improved signaling. Examples of SSRIs include citalopram, fluoxetine, 
sertraline, and paroxetine. SSRIs have wide applicability in mental health disorders 
and are effective in treating depression, OCD, post-traumatic stress disorder 
(PTSD), social phobias, eating disorders, and generalized anxiety. The side effects 
of SSRIs are relatively mild but still cause patients to stop taking the medication. 
More serious side effects include 5-HT toxicity syndrome and SSRI discontinuation 
syndrome. SSRIs are favored as the first-line intervention for depression given 
their efficacy, cost effectiveness, lack of dietary restrictions, and improved safety 
compared with MAOIs and TCAs. 
SNRIs function similarly to SSRIs but inhibit the reuptake of 5-HT, NE, and 
dopamine, increasing monoamine levels without disrupting monoamine oxidase 
activity. SNRIs include duloxetine and venlafaxine and, in addition to their function 
as an antidepressant, exert a pain-relief effect lending to their use in diabetic 




and include hypertension, sedation, and nausea. Withdrawal, in the form of flu-like 
symptoms and electric shock sensations, can occur in as little as one missed dose. 
 Atypical antidepressants include bupropion and mirtazapine. Bupropion 
increases NE and dopamine levels producing a stimulant-like state. Depending 
upon severity and recalcitrance, mood stabilizers, antipsychotics, and serotonin 
modulators may also be prescribed. The hallmark mood stabilizer is lithium which 
has a significant side effect profile but demonstrated clinical efficacy in treatment-
resistant depression. 5-HT modulators, such as trazodone, are often given as an 
adjunctive medication and improve well-being by altering 5-HT levels and 
promoting sleep.  
Psychotherapy 
Psychotherapy, though rarely prescribed in isolation, is a useful non-
medicinal adjunct to pharmacotherapy. Psychotherapy, its administration, and its 
efficacy can vary depending on the theoretical framework and experience-level of 
the therapist, but the treatment typically involves cognitive behavioral therapy 
(CBT), interpersonal therapy (IPT), and psychodynamic therapy (PT). Over many 
randomized controlled trials, some forms of psychotherapy, such as CBT, have 
been shown to be as effective as a course of antidepressants and can significantly 
improve short-term outcomes when used in conjunction with pharmacotherapy.9 
CBT finds its roots in both cognitive and behavioral psychology and attempts to 
identify maladaptive or dysfunctional thoughts or behaviors that promote or 




Myrna Weissman and focuses on attachment styles and ameliorating interpersonal 
issues. Therapists practicing IPT attempt to decrease depressive symptoms by 
guiding patients along interpersonal skill-building in four major areas of potential 
relationship difficulties: grief after loss, conflict in relationships, issues of social 
isolation, and inability to adjust to changes in relationships. Similar to IPT in its 
emphasis on interpersonal issues, PT focuses on the identification of unconscious 
conflicts that manifest as symptoms of depression. Drawing upon the teachings of 
Freud, free association and dream interpretation offer the therapist insight into the 
unconscious of the patient to assess maladaptive patterns of thought or behavior. 
Generally, these three forms of psychotherapy share strength of efficacy, and their 
effect size is augmented by concomitant pharmacotherapy. 
Electroconvulsive Therapy 
Reserved for severe, intractable cases often classified as treatment-
resistant, electroconvulsive therapy (ECT) is a safe intervention that can be used 
in addition to pharmacotherapy and psychotherapy. Studies have demonstrated 
that ECT is significantly more effective than pharmacotherapy alone, with 50%-
60% of patients achieving rapid remission with ECT compared with 10%-40% of 
patients receiving pharmacotherapy and psychotherapy.7,10,11  Patients often 
report a response in as little as one treatment, but typically an initial course of 5-
15 sessions is prescribed and is highly effective. Patients then follow a 
maintenance plan of roughly 15 sessions annually.12 ECT involves producing a 




anesthesiologist is required to administer the anesthesia as well as a light paralytic 
to prevent muscle contraction or a gran mal seizure, limiting the activity to the areas 
of interest. Side effects of ECT include retrograde amnesia, or the inability to 
remember events preceding the treatment. Though it is hard to argue with the 
results of ECT, its cost-effectiveness is a different story. Each session requires a 
fully equipped operating room or surgical suite, a psychiatrist, an anesthesiologist, 
and medications, creating an average cost of $2,500 a treatment according to 
Medicare.gov (https://www.medicare.gov). With a potential cost of $25,000 
annually compared with several hundred dollars for pharmacotherapy, it is not 
surprising that ECT use remains low and reserved for more severe cases.13 Of 
162,691 patients diagnosed with MDD, bipolar disorder, or schizoaffective disorder 
treated at general hospitals in the United States, only 1.5% underwent ECT during 
their initial admission in a 2017 analysis.14  
In use for over 75 years, the potent effects of ECT have been attributed to 
four main theories for its mechanism of action: the monoamine theory, 
neuroendocrine theory, and neurotrophic/neuroplastic theory.15 In accordance with 
the monoamine theory, ECT enhances the neurotransmission of dopamine, 5-HT, 
and NE, but the exact mechanism for this enhancement is hazy. Evidence that 
ECT modulates dopamine is apparent from its anti-parkinsonian and antipsychotic 
effects, which result from augmentation and detraction of dopamine signaling, 
respectively. In both animals and humans, ECT elicited widespread, complex 




post-synaptic neurons, levels of 5-HT metabolites, and alterations in 5-HT 
reuptake/transport. In a similar process to many antidepressants, ECT increases 
available 5-HT for signaling by further reducing receptor number even in patients 
with refractory depression. Studies of ECT have consistently demonstrated a 
downregulation of beta-adrenergic receptors and post-synaptic effects resulting in 
increased NE transmission in the cortex. Alterations in γ-aminobutyric acid (GABA) 
and glutamate neurotransmission contribute to aspects of the antidepressant and 
anti-convulsant effects of ECT. As a major inhibitory neurotransmitter, increases 
in GABA signaling following ECT have been associated with a reduction in anxiety, 
enhanced seizure threshold, and improved mood. Effects on glutamate signaling 
are unclear, as studies have reported opposing effects on glutamate levels 
following ECT. The neuroendocrine theory of depression revolves around 
dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and the potential 
release of an antidepressant neuropeptide, euthymesin, from the hypothalamus.16 
The release of prolactin, endorphins, adrenocorticotropic hormone (ACTH), and 
thyroid-stimulating hormone (TSH) that accompanies ECT treatment may be 
beneficial in mood disorders, as researchers have demonstrated an association 
between HPA dysregulation and depression.17,18 The neurotrophic theory of 
depression purports that impaired synaptogenesis and neuronal plasticity can 
result in major depression, and treatment methods, such as antidepressants, 
modulate plasticity to produce responses. Neuronal plasticity refers to the ability 




and improve neuronal network signaling in response to trophic factors released by 
environmental triggers. These neurotrophic factors are a protein family that 
promote the survival, growth, differentiation, and function of developing and mature 
neurons. The levels of neurotrophic factors, like brain-derived neurotrophic factor 
(BDNF) and glial cell line-derived neurotrophic factor (GDNF), can change with 
chronic stress and decrease, relative to the norm, in cases of untreated MDD.19,20 
Animal models using electroconvulsive shocks (ECSs), the animal analogue of 
ECT, demonstrated increased neurogenesis and sprouting of mossy fibers in the 
hippocampus of rats.21 
Despite the efficacy of ECT, therapeutic use remains low for reasons that 
are manifold: (1) public stigma continues to envelop the intervention in a shroud of 
desperation and inhumanity; (2) healthcare costs bar its entry into the ranks of 
inexpensive first-line treatments; and (3) inaccessibility or unavailability leaves 
many who would benefit without opportunity for response and potential remission. 
The answer to the immense need of patients and psychiatrists for an immediate, 
inexpensive, and effective treatment for depression does not lie in ECT, though 
the elucidation of its mechanism of action will offer guidance in the manufacture of 
future drugs and interventions.  
TREATMENT-RESISTANT DEPRESSION 
Treatment-resistant depression (TRD) is currently a nebulous descriptor for 
a significant subset of the population of those diagnosed with MDD. There has yet 




consensus defines TRD as a form of MDD in which patients do not respond to 
adequate treatment.22 Patients with TRD are twice as likely to be hospitalized, 
require significantly more outpatient visits, and require 1.5 to 3 times the amount 
of medication, lending to skyrocketing direct and indirect health costs. A 
retrospective analysis of medical claim data determined that the total depression-
related costs of TRD patients were 19 times higher than those of patients with 
MDD who were not treatment resistant.3 Depending upon the definition of TRD 
used, 12%-30% of depressed patients can be diagnosed with TRD.23,24 Severity 
of TRD can be staged according to the number and type of failed treatments as 





Table 2. TRD Stage Criteria 
 
This table shows the staging criteria for treatment-resistant depression. TRD = treatment-
resistant depression. Table taken from Ref. 25 (Blumberger et al., 2012). 
 
Approaches to managing treatment resistance fall into three major 
categories: dose optimization, class switching, and adjuvant medications. 
Increasing dosage of antidepressants is often the first line of defense for 
psychiatrists, as the dosage can be increased until intolerable side effects are 
reported, symptoms remit, or the upper limit of safe consumption has been 
reached. Freidman et al. surveyed participants at a psychopharmacology course 
and found that >80% of the providers selected increasing SSRI dosage as their 
first choice in response to a minimal effect after four weeks of treatment.26 Despite 
this resounding preference for titrating dosages, the surplus of randomized, 
double-blind studies investigating the efficacy of dose augmentation in the setting 




Constructed dose-response curves have been equivocal, with a study by Berney 
et al. producing a flat dose-response curve. Incremental dose increase 
predisposes patients to more significant side effects and, in some cases, can result 
in serotonin syndrome or seizures.  
Class switching refers to the process of changing to a different 
antidepressant, generally to a different drug family after an ineffective treatment 
course. The preferred methodology for class switching involves a gradual tapering 
off of the original medication, followed by a wash-out period before the new 
medication is instituted. Issues with class switching typically pertain to the ethics 
and efficacy of the process. The tapering off and wash-out periods can leave 
patients susceptible to withdrawal symptoms and relapse or exacerbation of their 
underlying psychiatric illness. Thus, many providers attempt to proceed more 
rapidly in order to avoid these issues, but inadequate wash-out times can lead to 
undesirable drug-drug interactions. Conservative approaches to class switching 
involve a washout-period lasting five half-lives of the drug, whereas more 
aggressive approaches involve a wash-out period of only 2-4 days. The half-lives 
of antidepressants can be anywhere between half a day and two weeks depending 
on the drug and class.27 Class switching, similar to dose augmentation, lacks 
established efficacy, as Souery et al. found no significant difference in response or 




antidepressant and those switching “within-class” to an antidepressant of the same 
class.28  
Another level of optimization is introduced in the third aspect of 
pharmacological management of TRD in which adjuvant medications are 
prescribed with varying efficacy to augment the mood-boosting effects, or lack 
thereof, of the current regimen or address other symptoms or side effects. 
Common adjuvant medications and their strengths of efficacy are seen in Table 3, 
with each medication representing a new layer of complexity to the process that 
places additional load on physicians, patients, and the healthcare system. The risk 
of polypharmacy envelops the process as providers balance effects of different 
pathways and genetics.  
Lithium is a time-honored adjuvant medication for TRD. With its first 
reported trial in 1981, lithium was hypothesized to work in concert with TCAs, 
improving serotonergic signaling in the brain.29 Lithium, being an element, is 
ingested as a salt and results in non-specific modulation of serotonergic and 
noradrenergic signaling. Its therapeutic use falls within a narrow plasma 
concentration of 0.5 to 1.0 mEq/L.30 Beyond a concentration of 1.5 mEq/L, 
symptoms of lithium toxicity begin to set in, so regular plasma monitoring is 
essential. Its robust efficacy is offset by its antiquity and treatment burden, 
particularly as SSRIs quickly supplanted TCAs and regular plasma level 
monitoring, lithium raised concerns about cost and adherence. Studies of lithium 




with some demonstrating no clear advantage over dose increase. Fava et al. found 
this to be to the case when lithium was combined with fluoxetine or desipramine 
treatment.31,32 Considering the lackluster efficacy of lithium when used with the 
more common SSRI-based treatment strategies and its associated inconvenience, 
it is hard to justify intrusive neurologic and gastrointestinal side effects for a 
response that is increasingly more unlikely with each successive approach. 
However, such justification occurs in the desperation to pharmacologically 
managed patients before proceeding with more aggressive approaches.  
Table 3. Efficacy of Various Interventions in TRD 
Drug Strength of Efficacy in TRD 
Lithium A (with TCA) 
 C (with SSRI) 
Atypical Antipsychotics A (quetiapine and olanzapine) 




Thyroid Hormone B (with TCA) 





This table summarizes the efficacy of various medications in treatment-resistant 
depression. Strength A represents very strong efficacy, strength B represents strong 
efficacy, and strength C represents moderate to neutral efficacy. SSRI = selective 
serotonin reuptake inhibitor; TCA = tricyclic antidepressant; TRD = treatment-resistant 





Established treatment regimens continue to fail patients with MDD and TRD 
by increasing risks of morbidities, mortality, and side effects while accomplishing 
very little in the arena of depression symptoms. To address the dire circumstances 
of these patients and escalating health-care costs, the FDA has expedited the 
approval of novel treatments, like ketamine, favoring immediate promise over long-
term investigations of safety. Given the illicit status of ketamine, established 
anesthetic use, and potentially rapid antidepressant effects, clinical ketamine trials 
were designed to characterize the acute changes resulting from treatment that 
would warrant the approval of another drug with abuse potential during the opioid 
epidemic, particularly for a patient population that was disproportionately affected 
by substance abuse disorders. The relationship between ketamine abuse and 
irreversible bladder damage has been well documented, albeit at significantly 
larger doses and over a longer duration than the 3-month trials of nasal ketamine 
administration for TRD. The source of this urological pathology remains unclear 
but must be determined before patients consent to treatment in order to prevent 
additional harm to an already ailing population. To realize the link between 
ketamine use and bladder damage, it is necessary to begin with the basic function 
of the lower urinary tract. 
ANATOMY AND PHYSIOLOGY OF THE LOWER URINARY TRACT 
 From an anatomic standpoint, the lower urinary tract consists of a storage 




urethral sphincter, partly controlling the transition from storage to voiding. This 
model, though extremely simplistic, is a decent foundation upon which to begin. 
The Bladder  
The bladder is physically located within the retroperitoneal cavity, bordered 
dorsally by the rectum in males and the vagina and uterus in females, and ventrally 
by the pubic symphysis and portions of the pelvic floor or the prostate in females 
and males, respectively. The peritoneum is draped over its dorsal surface, 
whereas its inferior, ventral face is encased in the endopelvic fascia.34 The bladder 
is fixed anteriorly within the retroperitoneal cavity by the median umbilical ligament 
and surrounded by loose connective tissue and subcutaneous fat that forms an 
adventitia. The areas intersecting with the peritoneum are lined with serosa. The 
loose connective tissue of the adventitia provides a scaffold of collagen and elastin 
that is flexible enough for the elastic demands of voiding cycles but also serves as 
an anchor that facilitates muscular and ligamentous connections to the pubic 
symphysis, prostate, rectum, and pelvic floor, fixing it within the retroperitoneal 
cavity and directing a cranial expansion during filling.35 The bladder itself is a 
hollow, muscular organ that stretches to accommodate urine storage and by 
contracting, with some conscious input, to actively participate in voiding. These 
two antagonistic functions necessitate the precise integration of sensory, 
parasympathetic, sympathetic, and conscious input to retain “normal’ voiding 
patterns. The bladder is anatomically divided into four regions: the body, fundus or 




and comes forward toward the abdominal wall. The body is a large area that is the 
intermediary of the apex and fundus.34 The fundus consists of the deep detrusor 
muscle, anterior bladder wall, urethrovesical junction, and trigone.36 The trigone is 
a smooth area of the internal surface of the fundus that forms the junction between 
the two ureteric orifices and the internal urethral orifice. The neck is continuous 
with the urethra and forms the musculature of the internal urethral sphincter. The 
urethral sphincter anchors the bladder inferiorly to the pelvic floor in females and 
to the prostate in males. 
The average bladder capacity of an adult is approximately 500 mL, though 
the bladder is capable of significant deviations from this mean in cases of 
pathology and in daily voiding cycles. Post-void, the mucosa of the bladder 
resembles that of the stomach as the tissue is thrown into folds, or ruggae. The 
metabolic needs of the bladder are met by the blood supply of the superior and 
inferior vesical arteries which arise directly, or indirectly, from the internal iliac 
arteries. Venous drainage occurs through the vesical venous plexus which is 
continuous with the internal iliac vein.34 Neurological innervation of the bladder is 
accomplished by sympathetic and parasympathetic input and sensory output. 
Tonic sympathetic innervation, generated by the sympathetic ganglia of levels T12-
L2, arrives from the hypogastric nerve and relaxes the bladder to promote urine 
retention. Parasympathetic influence from the sacral spinal cord (S2-4), 
transmitted through the pelvic nerves, control bladder contraction and trigger 




status of the bladder transduced by stretch and tension of muscle spindles in the 
detrusor. Neural regulation of the lower urinary track is discussed in further detail 
in the Micturition section. 
The Detrusor Muscle  
Beneath the adventitia and serosa of the bladder lies the muscularis 
composed of three layers of the detrusor muscle oriented with inner and outer 
longitudinal muscle layers intercepted by a middle circular layer. These muscles 
function in concert to produce the semi-radial contraction required for voiding.36 
The detrusor demonstrates features of single- and multi-unit smooth muscle, with 
muscle cells electrically connected via gap junctions comprised of connexin 
proteins to promote synchronous contraction. The detrusor muscle can generate 
spontaneous activity triggered by stretch and has dense autonomic innervation 
that is required to coordinate voiding.36  
The urinary bladder demonstrates relatively fast contractile mechanics 
indicative of phasic smooth muscle phenotype. Contraction of the urinary bladder 
relies on the interaction between thick filament, myosin, and the thin filament, actin 
to shorten in a power-stroke fashion. In lieu of the regular sarcomeric 
arrangements of actin and myosin in skeletal muscle cells, smooth muscle cells 
contain an elaborate internal scaffold of actin that is anchored to the membrane by 
α-actinin-rich dense bands that function similarly to the Z-discs of sarcomeres. 
Dense bands serve to fix thin filaments to the sarcolemma at zonula adherens and 




a similar role in force transduction but are free within the cytoplasm. The length of 
each contractile unit is a crucial determinant of maximal shortening velocity and 
the force-length interval of smooth muscle. The actin concentration in the detrusor 
muscle cells is comparable to that of skeletal muscle, while the myosin content is 
three to five times less.37,38 In the human detrusor, the actin concentration is split 
across four different isoforms: α, β, and two forms of γ (muscle and non-muscle 
actin), at a distribution of 33:25:42, but the consequences of this proportion remain 
to be elucidated.39 It seems likely that composition of actin is not a major 
determinant of force generation or shortening velocity, since actin is highly 
conserved, the isoforms share significant sequence homology, and in vitro motility 
assays have demonstrated comparable filament translocation to skeletal 
muscles.40–42 The random arrays of actin within the cell permit multi-dimensional 
contraction and allow extensive shortening over a wide range of rest-lengths, 
unparalleled in skeletal muscle.  
A member of the myosin II family of thick filaments, smooth muscle myosin 
polymerizes with its globular head regions protruding at 14-nm increments.43 
These globular head regions contain a nucleotide binding site for adenosine 
triphosphate/diphosphate and actin binding sites forming cross-bridges. Myosin is 
a hexamer consisting of two heavy chains and two pairs of light chains. The heavy 
chains are encoded by a single gene (SM-MHC); however, alternative splicing of 
the 43 amino acid carboxy-tail region, which functions as a site of phosphorylation 




consequences of these isoforms and their prevalence in detrusor have yet to be 
determined. Additionally, SM-A and SM-B heavy chain isoforms can result from 
alternative splicing of a seven amino acid insert in loop 1 encoded by exon 5B in 
the amino-terminus, with the insert present in SM-B and absent in SM-A. Both SM-
1 and SM-2 isoforms of myosin heavy chain contain the splice site, resulting in 4 
possible isoforms of myosin heavy chain within the detrusor: SM1-A, SM2-A, SM1-
B, SM2-B. The insert in SM-B forms is hypothesized to augment the kinetics of the 
actin-myosin interaction with the loop 1 insert demonstrated increased velocity of 
actin propulsion and its expression correlates with maximal shortening velocity. 
Relative levels of SM-B in the detrusor muscle can range from 80% to 90% 
corresponding to the detrusor’s “fast” phenotype. The heavy chains intertwine in 
alpha-helical fashion to form the backbone of the thick filaments.  
The essential light chains are of two flavors and are of equal size: acidic 
LC17a and basic LC17b. Formed via alternative splicing and differing by only nine 
amino acids in their carboxy-termini, the light chains pair randomly on myosin 
heavy chains.48 LC17b is considered a non-muscle isoform and is associated with 
slower contractile kinetics.36,49,50 As a fast smooth muscle, the relative contribution 
of LC17b is low, around 10% for the rat bladder, and may serve as a marker, along 
with non-muscle myosin isoforms, for non-smooth muscle cells that potentially 
differentiate into smooth muscle cells and may be implicated in aspects of bladder 
hypertrophy.36,51  In addition to anchoring the contractile units, dense bands serve 




as integrins, actin, tensin, calponin (CaP), and vinculin.52 Urinary smooth muscle 
cells contain a cytoskeletal lattice of desmin that plays a crucial role in the 
generation of active force. Desmin-deficient visceral smooth muscle, in a mouse 
model, produces significantly less contractile force and reduced shortening 
velocity.52 In addition to active force production, the cytoskeleton, and its plethora 
of membrane attachments, transmits this force to the interstitial matrix and serves 
as a hub for signaling, gene expression, chemotaxis, and growth.36 Other 
cytoskeletal elements such as CaP, a 34-kDa actin-binding protein, serve as 
regulators of contraction. CaP has an actin-binding domain and myosin ATPase 
inhibitory activity at its carboxy terminus and two binding sites for calcium-binding 
proteins such as calmodulin at its amino terminus allowing it to function as a 
regulator and amplifier of contraction.53,54  
 Force generation is intrinsically linked to active cycling of interactions 
between actin subunits and globular myosin heads as part of a process called 
cross-bridge cycling that is fueled by the constant hydrolysis of adenosine 
triphosphate (ATP) to adenosine diphosphate (ADP) and an inorganic phosphate 
(Pi). After activation, the globular heads of myosin, in the ADP and Pi bound-state, 
demonstrate increased affinity for the active site of actin, binding at a right angle 
to the thin filament. The dissociation of the Pi, after binding, triggers a 
conformational change in myosin that causes a change in the binding angle of the 
globular head to 45°, sliding the thick filament along the thin filament. In order to 




hydrolysis reorients the power-stroke for another cycle. For maximal force 
production, the intracellular ATP concentration must be kept sufficiently high to 
keep the equilibrium constant favoring its dissociation and ADP concentration must 
be held within a narrow index, as small changes can lead to vast alterations in 
force production. Rigor, caused by the depletion of ATP and increase in ADP, locks 
actin to the myosin-ADP complex and inhibits cross-bridge cycling. The rate of 
cross bridge cycling in the rabbit urinary bladder is dictated by a second order rate 
constant of 1 x 105 M-1s-1, which is five times slower than skeletal muscle, but 
corresponds to the bladder’s fast phenotype relative to other smooth muscles.55 
The maximum velocity (Vmax) of the power stroke is defined as the rate of actin-
propulsion by myosin under minimum load. In vitro measurements of the urinary 
bladder muscle have yielded a Vmax of 0.2 muscle-lengths per second56, while the 
Vmax of vascular smooth muscle is roughly five times slower.57  Vmax is limited by 
the rate of cross-bridge dissociation and there is a strong correlation between Vmax  
and the rate of ADP dissociation from myosin.36 The urinary bladder demonstrates 
low ADP binding in rigor and in the dephosphorylated state relative to arterial 
muscle.58,59 Overall the detrusor can be described as having a low affinity for 
ADP58,59, a high affinity for ATP55, and high Pi sensitivity. As such, the 
concentrations of these molecules are ultimate determinants of shortening velocity 
and force generation.55,58–61   
ATP is a protean fuel source, powering diverse processes in the detrusor 




cycling, calcium (Ca2+) handling, and phosphorylation reactions, the demand for 
ATP is maintained through the metabolism of glucose which steadily enters the 
cells via non-insulin-dependent glucose transporter 1 (GLUT1) and is broken down 
through oxidative phosphorylation, glycolysis and phosphocreatine (PCr).36 In the 
rabbit urinary bladder studies have revealed that 81% of glucose is metabolized 
anaerobically to lactate, 11% completes oxidative phosphorylation, and 4.7% is 
stored as glycogen.62 Overall the majority of ATP generated is produced by 
oxidative phosphorylation despite the disproportionate metabolic ratios given its 
much greater efficiency and yield. During bladder contraction, ATP levels do not 
change significantly, though PCr levels may drop by as much as 30%.36,63  The 
rate of oxygen (O2) consumption of the relaxed rat detrusor muscle in the presence 
of glucose is 1.5 nmol/min*mm3 while the rate of lactate production is 0.5 
nmol/min*mm3 but during active contraction these rates increase by two- and 
three-fold, respectively.64 Intracellularly, the pH of human detrusor cells is roughly 
7, but in vitro studies have demonstrated that intracellular acidosis and 
extracellular alkalosis can improve force generation by augmenting Ca2+ uptake 
and release. On the other hand, shift in intracellular pH towards the alkalotic, or 
acidification of the extracellular environment, as can be seen in hypoxia, results in 
reduced force generation by diminishing Ca2+ flux by means of L-type membrane 
channels.65–68   
According to the law of Laplace, the wall tension of the bladder is dependent 




pressure and volume relationships as a proxy for muscle length and force 
production. There is a non-linear relationship between stretch and passive tension 
in the bladder wall, with lengths above that of maximum force generation producing 
a steep increase in passive tension.69,70 The passive tension in the detrusor arises 
primarily from the extracellular matrix (ECM) with some contributions by the 
number of resting cross-bridge interactions and cytoskeleton. Type I and type II 
collagen and elastin imbue the ECM with its tensile properties, and are distributed 
throughout the serosa, between muscle bundles, and interstitially.71–73  Despite 
being able to contract and generate force over a significant length interval, the 
active force generated by the detrusor is critically dependent upon wall stretch. 
Wall stretch is reflected in increased filament overlap and cross-bridge interactions 
until reaching its pinnacle, where after it falls off sharply. At optimal length, the 
human detrusor can generate 200 mN/mm2 which is a result of the number of 
cross-bridge interactions acting in parallel and the intrinsic force generation of each 
cross-bridge.74 The Vmax of detrusor contraction reflects the mode of stimulation, 
the time after stimulation, and current muscle length, with mode of stimulation 
being the primary determinant. The Vmax of an intact rabbit bladder is roughly 0.3 
muscle lengths per second and is higher following electrical stimulation than after 




active force and shortening velocity, with Vmax occurring at zero load and isometric 
force at zero velocity (P0).  
Pathophysiological Adaptations of the Bladder 
 Studies of the bladder under pathological conditions and following surgical 
procedures have revealed it to be a highly adaptive organ capable of partial 
regeneration and immense growth. In pathological states, such as decentralization 
following a spinal cord injury (SCI) or outlet obstruction, chronic stretching of the 
detrusor serves as the primary induction factor for hypertrophy and hyperplasia, 
producing this effect rapidly through a variety of signaling cascades involving 
growth factors such as epidermal growth factor (EGF) and insulin-like growth factor 
I (IGF-I).36,78–80 In a rat model of outlet obstruction by Polyanska and colleagues, 
bladder weight increased two-fold over a ten day period.81 This growth, though 
dramatic, has been demonstrated to be both reversible and preventable in animal 
models of outlet obstruction and decentralization, respectively. Rats, when 
obstructed infravesically, exhibit reversible hypertrophy and hyperplasia of the 
detrusor following relief of obstruction, regaining relatively normal bladder weight 
and protein composition upon the restoration of normal flow and cessation of 
chronic stretch.39,82,83  Nonetheless, these “restored” rat detrusors remain 
functionally and histologically abnormal relative to controls.84 In cases of spinal 
cord injury or experimental denervation, detrusor hypertrophy and hyperplasia 
occurs irrespective of the trophic influences of the parasympathetic nervous 




the role of stretch as a growth inductor.85–87 As the detrusor hypertrophies, 
transcription and translation in smooth muscle cells are thrown into overdrive 
increasing the production and decreasing the degradation of cytoskeletal and 
contractile proteins. Though the total concentration of contractile elements 
increases, hypertrophy causes decreased maximal shortening velocity due to 
changes in length and the isoform expression of contractile proteins.56 In 
obstructed rat bladders, there is amplified expression of light chain LC17b and 
heavy chain SM-A which are both correlated with a slower contractile 
phenotype.39,88 It is easy for hypertrophy to overshadow hyperplasia, particularly 
in the detrusor, but following injury or procedures likes grafts or partial 
cystectomies, its regenerative capacity is on full display.89,90 It is thought that 
mesenchymal cells of the serosa first proliferate then mature towards a smooth 
muscle phenotype as they begin to express smooth muscle actin and non-muscle 
myosin and upregulate vimentin.91 Beyond the smooth muscle cells, stretch 
induces increased deposition of collagen and elastin in the extracellular matrix, 
thickening the bladder tissue layers. Neovascularization quickly ensues spurred 
on by local growth factors and metabolic requirements of the hypertrophic tissue. 
This process is initially successful, as blood flow to the bladder reportedly 
increases in the partially obstructed rabbit bladder. Though in as little as ten to 
fourteen days of obstruction onset, the microcirculation begins to fail and evidence 






Several hundred microns in length, at rest, the long spindle-shaped muscle 
cells of the detrusor are immensely heterogeneous in composition and orientation, 
existing as a spectrum with well-defined muscular layers within the bladder neck, 
randomly-oriented fascicles composing most of the muscularis of the bladder wall, 
and trigone with its elaborated lamina propria and muscularis mucosa and lower 
smooth muscle content.35,93 On a microstructural level, bundles of smooth muscle 
cells ranging in size and organization enveloped in collagen-rich connective tissue. 
In the human, these main bundles of smooth muscle cells can be several 
millimeters in diameter at rest and composed of smaller functional units of smooth 
muscle cells, or fascicles.36,51,60,94  The membrane of each detrusor muscle cell is 
pockmarked with invaginations of membrane, less than 100 µm in diameter, called 
caveolae that function to bring a variety of gated-ion channels into close proximity 
with the cell’s internal contractile machinery and sarcoplasmic reticulum to facilitate 
expedient signal transduction. 
As a smooth muscle, detrusor contraction is initiated on a cellular level by 
a rise in intracellular Ca2+ resulting from its release from ntracellular stores in the 
SR of each smooth muscle cell. The release of SR stores can generally occur as 
a result of two different mechanisms: Ca2+-induced calcium release through gated-
ion channels and activation of G protein-coupled receptors (GPCRs) their 
associated signaling cascades, indicated in Figure 2.95 Activated by changes in 




dihydropyridine receptor (DHPR), line the invaginations of caveolae and are 
tethered to ryanodine receptors carpeting the SR. Upon activation, the DHPR 
undergoes a conformational change that is communicated to ryanodine receptors, 
effectively popping the cork ona bottle of sarcoplasmic calcium champagne. In the 
other arm of activation ligand binding to heterotrimeric receptors activates residues 
that function as guanine exchange factors (GEFs) that replace the guanosine 
diphosphate (GDP) on the inactive α-subunit of the undissociated G-protein with 
guanine triphosphate (GTP). In the detrusor, the Gq/11 flavor of GPCRs is preferred 
for contraction. Upon GTP exchange, the α-subunit activates phospholipase C-β1. 
Activated at the membrane, phospholipase C cleaves available 
phosphatidylinositol 4,5-bisphosphate (PIP2) present in the cytoplasmic face of the 
cell membrane, hydrolyzing the phosphodiester bond between diacylglycerol 
(DAG) and inositol triphosphate (IP3), both of which serve as secondary 
messengers in a variety of different signaling cascades, with only those of the latter 
being related to contraction. IP3 accumulates in the cytoplasm and activates IP3-
gated Ca2+ channels present on the SR, releasing its stores. Here the two 
activation pathways overlap and often sum as calmodulin, inactive in an un-bound 
state, interacts with the free intracellular Ca2+ and undergoes a conformational 
change that activates its endogenous kinase activity. In this active state, Ca-
Calmodulin phosphorylates myosin light chain kinase (MLCK). Phosphorylated-
MLCK phosphorylates the regulatory light chain of myosin at serine-(Ser)19, 




propelling actin until signal termination or dephosphorylation.96,97 MLCK contains 
a regulatory site, A, which upon phosphorylation conveys reduced affinity between 
MLCK and Ca-Calmodulin and reduces Ca2+ sensitivity.98–100 Protein kinase A 
(PKA), Ca2+/calmodulin-dependent kinase II (CaMK II), P-21 activated kinase 
(PAK), and mitogen-activated protein kinase (MAPK) are all capable of 
phosphorylating site A on MLCK; in vitro MAPK appears to exert an activating 
effect on MLCK while the others produce decreased Ca-sensitivity.101–104 Myosin 
light chain phosphatase (MLCP) serves as the break for muscle contraction, 
removing the phosphate from regulatory MLCs and terminating cross-bridge 
cycling. The MLCP expressed in the detrusor is a trimeric type 1 protein 
phosphatase consisting a 37-kDa catalytic subunit, a 120-kDa regulatory subunit, 
and a measly 20-kDa subunit that is for all intents-and-purposes irrelevant in the 
scheme of this review.105 The regulatory subunit can be reversibly phosphorylated 
and serves to facilitate the interaction between non-phosphorylated, active MLCP 
and regulatory MLCs, leading to its apt moniker, myosin light chain phosphatase 
targeting protein (MYPT). Rho-associated kinase (ROK) has a well-documented 
ability to phosphorylate MYPT, thus playing an integral role in modulating the Ca2+-
sensitivity of the detrusor muscle cells; increasing Ca2+-sensitivity by decreasing 
MLCP activity.85 ROK is itself regulated by small G-proteins belonging to the Rho 
subcategory of the Ras family of GTPases.106  Rho is activated through GTP-GDP 
exchange that is controlled by usual suspects of guanine exchange factors (GEFs), 




Prior to activation, Rho floats freely in the cytoplasm in its GDI-GDP bound state. 
Rho-GEF facilitates the exchange of GDP for GTP, when present, on Rho which 
initiates membrane translocation. At the membrane, Rho-GTP phosphorylates 
ROK which can then phosphorylate MYPT region of MLCP, inhibiting its 
activity.106,108 There are two forms of ROK expressed in the urinary bladder; rho-
associated kinase-1 (ROCK-1) and rho-associated kinase-2 (ROCK-2). Inhibition 
of these kinases in vitro prevents detrusor contraction elicited by both 
electrostimulation and carbachol, a muscarinic receptor agonist, demonstrating 
ROK’s integral role in Ca2+-sensitivity and excitation-contraction coupling of 
muscarinic receptors.109,110 An additional source of MLCP inhibition, and altered 
Ca2+-sensitivity, is derived from the activation of a robust phosphorylation-
dependent protein phosphatase type one inhibitor, C-kinase-potentiated Protein 
phosphatase Inhibitor(CPI)-17.111 Phosphorylation of CPI-17 at threonine (Thr)-38 
is accomplished primarily by protein kinase C (PKC), which is itself regulated, and 
also by protein kinase N (PKN) and ROK in vitro.112,113 CPI-17, unlike ROCK, is 
capable of inhibiting activated MLCP and the inactive holoenzyme.114 Other levels 
of modulation for contraction exist, including stretch-activation of the ryanodine 
receptor through mechanical coupling to the membrane, which amplifies Ca2+ 




inhibits the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump, prolonging 









Figure 2. Excitation-contraction coupling. Ca2+ release from the SR can be mediated 
by Ca2+-induced Ca2+ release or IP3 production. The previously sequestered Ca2+ binds to 
calmodulin and activates MLCK, enabling cross-bridge cycling. Rho signaling serves to 
increase contractility by inactivating MLCP, empowering MLCK, and amplifying active 
cross-bridge sites. ATP = adenosine triphosphate; DG = diacylglycerol; MLC = myosin 
light chain; MLCK = myosin light chain kinase; MLCP = myosin light chain phosphatase, 
PKC = protein kinase C. Figure taken from Ref. 36 (Andersson & Arner, 2004).  
 
The Bladder Mucosa 
The urinary tract is lined by a specialized transitional epithelium, or 
urothelium, that begins in the renal pelvis and terminates at the external urethral 
orifice. The urothelium forms a highly resistive, distensible barrier that prevents 
solute, ion, and water exchange between volatile, lumenal urine and the 
submucosa and blood supply, despite large changes in bladder volume. Armed 




complexes, and surface plaques, the urothelium initially appeared impenetrable. 
Further investigations, however, revealed it to not only be an active participant in 
solute and water exchange but also to function as a sensory apparatus that 
provides real-time feedback about urine composition and volume to the underlying 
layers of bladder cells.117  Though the classification of transitional epithelium 
connotes that the urothelium is pseudostratified, further inspection proved it to be 
more stratified than previously thought.118 The urothelium is trilaminar, consisting 
of a basal layer of immature and stem cells, an apical layer of highly differentiated 
umbrella cells, separated by intermediate cells which lie in reserve ready to replace 
the umbrella cells when needed.119 It appears that only the basal layer, and 
occasional intermediate cell, maintain attachments to the basement membrane as 
indicated by the presence of hemidesmosomes, while umbrella cells are anchored 
basally to underlying intermediate cells by desmosomes.120,121  
Umbrella cells, or facet cells, comprise a single polarized layer of highly 
differentiated cells riveted together by highly resistive tight junctions, or zonula 
occludens.122 These cells are mononuclear and their morphology and size vary 
corresponding to bladder volume, ranging from around 150 µm in diameter and 
cuboidal when the bladder is empty to 25 µm and squamous when filled.123,124 At 
their apicolateral junctions, the membranes of adjacent umbrella cells interdigitate 
forming a zipper-like ridge several hundred nanometers in length that covers tight 
junctions and improves resistance to paracellular transport. Normally, the apical 




plaques that swell the external cell membrane leaflet to twice the size of the 
internal, producing an asymmetric unit membrane (AUM)125,126. This elaboration of 
the outer leaflet occurs as it accommodates AUM particles as they assemble into 
crystalline inner and outer membrane rings.127,128 A plaque consists of around 
2,000 AUM particles that primarily belong to the uroplakin (UP) family of 
transmembrane proteins: UPIa, UPIb, UPII, UPIIIa, and UPIIIb. In the human 
urothelium, monomeric UPs interact forming heterodimers that interact to form an 
inner ring of UPIa-UPII and outer ring of UPIb/UPIIIa heterodimers.117 The apical 
membranes of umbrella cells do not interact strongly with detergents, reflecting a 
composition comparable to myelin but distinguishable, as it is enriched in 
cholesterol, cerebrosides, phosphatidylethanolamine, and 
phosphatidylcholine.129,130 In addition, the apical pole of the cell membrane 
displays little actin association and the cytoplasm abutting it is relatively devoid of 
cytokeratin. 
In order to maintain barrier and sensory functions over a range of bladder 
volumes, urothelial cells have a unique ability to transport plaque-laden vesicles to 
and from the cell membrane to meet the demands of voiding.123,124 Named for their 
shape, discoid-fusiform shaped vesicles (DFVs) are associated with a network of 
parallel cytokeratin-7 and cytokeratin-20 tunnels, running perpendicular to the 
apical membrane, that serve to direct vesicles to and from the lumenal 
membrane.131,132 Inferior to the umbrella cells lay multiple layers of intermediate 




intermediate cells anchored to surrounding cells by desmosomes.120 During filling, 
the layers appear thin and form a singular strip. Intermediate cells are partially 
differentiated and can express uroplakins, allowing them to replace the umbrella 
cells rapidly in the case of injury or normal turnover. Undifferentiated basal cells 
are approximately 10 µm in diameter and adhere to the basement membrane 
basally with hemi-desmosomes.120 The composition of cytokeratin filaments varies 
between layers and can serve as a marker of location in addition to those of 
differentiation. Basal cells can be identified through expression of cytokeratins -5, 
-14, and -17, and umbrella cells can be distinguished by cytokeratin-20 expression, 
whereas expression of cytokeratins -7, -8, -18, and -19 occurs throughout all cell 
layers.131  
Stem Cells and Repair 
For an epithelium, the urothelium exhibits a low rate of cellular turnover; a 
process taking 3-6 months to complete.133 Following injury, the urothelium displays 
an immense regenerative capacity that can restore integrity within days of initial 
insult.134 Ensconced by several cell layers and the subepithelium, urothelial stem 
cells are well protected and are anchored to the basement membrane by hemi-
desmosomes and β4 integrins.135 Their high β4 integrin content can serve as an 
identifier in addition to elevated forkhead box protein A1 (FOXA1) and p63 
expression.136 The outermost intermediate cells act as reserves and hastily replace 
umbrella cells in response to normal attrition or injury.137,138 Experiments involving 




sulfate and chitosan, have helped to elucidate the regenerative mechanism. These 
compounds permeabilize umbrella cells leading to shedding of the entire cell layer 
within an hour after exposure.139,140 In a response that is notable after a day, 
uroplakin monomers, primarily UPIIIa, are drawn from a cytoplasmic pool of newly 
exposed intermediate cells and distributed into their apical membrane while zonula 
occludens-1 (ZO-1) begin to repopulate apicolateral junctions.140 It is believed that 
the rapid differentiation of these intermediate cells occurs through both growth 
signals and loss of overlying cell-cell contact.  
Forming a barricade between urine and the submucosa, the urothelium 
regulates the transepithelial movement of ions, solutes, and water. Originally, the 
high resistance of the seemingly impermeable urothelium contributed to an 
assumption that urine composition was unchanged after production in kidney. 
Although umbrella cells proffer the main source of resistance to trans- and 
paracellular transport, their apical membranes contain a variety of ion channels 
and aquaporins that may play a larger role in homeostatic mechanisms than 
previously imagined. These cells interact with a large volume of ever-replenishing 
urine for long durations as dictated by voiding cycles over a very large surface 
area. Transport pathways for sodium (Na+), chloride (Cl-), potassium (K+), urea, 
water, and creatinine have been described in the urothelium and are believed to 
manage the large, fluxing concentrations of ions and solutes that correspond to 
physiological state and hydrostatic pressure.141–146 The plaque-thickened and 




ranges between 20,000 and 75,000 Ω∙cm2, while numerous adhesion structures 
between cells yield parallel junctional resistance that is near infinite.141,142   
The Urethra 
 The urethra is a fibromuscular connecting duct that conveys urine from the 
bladder to the external urethral meatus and contains two sphincters to permit 
transit. In males, the urethra is elaborated to accommodate prostatic regulation 
and is approximately 10-20 cm in length.34 Sub-classified into regions, the male 
urethra consists of a prostatic, membranous, and penile urethra, listed from 
proximal to distal. The female urethra is much shorter than that of males, 
approximately 4.6 cm, and predisposes females to urinary tract infections.147  
The more proximal, internal urethral sphincter consists of a stratum of 
smooth muscle that encircles that bladder neck and the internal orifice of the 
urethra. The status of the internal urethral sphincter involves both sympathetic and 
parasympathetic innervation.148 NE released tonically from sympathetic axons 
binds to α1-adrenergic receptors causing depolarization of smooth muscle cells 
and subsequent contraction of the sphincter.149 During voiding, parasympathetic 
release of nitric oxide interrupts tonic contraction to permit urine passage by 
hyperpolarizing the smooth muscle cells of this sphincter. 
 The external urethral sphincter is located in the membranous portion of the 




in males for purposes of ejaculation, investments of skeletal muscle constitute the 
external urethra allowing somatic regulation through the pudendal nerve.149 
MICTURITION  
Empty State  
Following a void, the bladder contains minimal residual volume that 
produces little stretch on the bladder wall as it returns to its resting tension. The 
decrease in tension and stretch results in decreased activation of 
mechanoreceptors within the detrusor muscle. The intra-ganglionic laminar 
endings and intramuscular arrays render the empty status through reduced 
afferent action potential frequency traveling from the bladder to synapsing on 
interneurons in dorsal horns of the sacral spinal cord at S2-S4.149 From here, the 
resultant sensory information is transferred up the spinal cord to synapse in the 
lateral horn of the grey matter of the thoracolumbar spinal cord at levels T11-L2.  
Interneurons at this level incorporate the incoming information regarding bladder 
status into an efferent sympathetic reflex at the level of the inferior mesenteric 
ganglion.149 
Projections from the inferior mesenteric ganglion travel as the hypogastric 
nerve back to the detrusor muscle, with a branch also innervating the internal 
urethral sphincter in men. At these adrenergic junctions, NE is released from 
synaptic terminals and binds to the β3 receptor present on the detrusor muscle, 




encourages further accommodation of urine.148 At the internal urethral sphincter, 
released NE binds to α1 receptors, triggering involuntary contraction to prevent 
leakage into the pre-prostatic urethra. In addition to participating in a filling reflex, 
sensory information ascends the spinal cord, synapsing in the brainstem on 
pontine interneurons, while others synapse in the thalamus before transmitting this 
sensory information to the cortex, producing conscious awareness. During the 
empty or filling state, afferent information arriving in the pons is diverted to two 
specific grey matter centers: the pontine micturition center and the pontine storage 
center.149 
The pontine storage center is stimulated under empty conditions and sends 
descending motor efferent signals to the thoracolumbar and sacral spinal cord. 
The pontine micturition center, controlling voiding behavior, receives inhibitory 
input, effectively silencing its parasympathetic motor efferents to the sacral spinal 
cord and detrusor muscle and releasing the thoracolumbar neurons projecting to 
the inferior mesenteric ganglion from inhibition, promoting further detrusor 
relaxation.148 In addition, cortical input, indicating a desire to hold, amplifies the 
pontine signaling, which inhibits the micturition center and stimulates the storage 
center. Inhibitory signaling from the storage center descends the spinal cord to the 
sacral region before decussating and inhibiting preganglionic parasympathetic 
neurons in the lateral grey matter. The cascade of inhibition follows to the 
postganglionic neurons whose projections travel as the pelvic nerve to the detrusor 




muscarinic receptors present on the detrusor go unstimulated, and intracellular 
calcium levels go unaltered. Excitatory input in descending fibers from the storage 
center arrive at the sacral spinal cord and stimulate alpha motor neurons in the 
anterior horn whose projections form the somatic motor branch of the pudendal 
nerve. Here conscious input is integrated into the system as the pudendal nerve 
travels to the external urethral sphincter, stimulating contraction by means of ACh 
binding to nicotinic receptors and forming a second line of defense against 
leakage.149 This feedback loop promoting filling continues as urine produced by 
the kidneys arrives from the ureters and discharges into the bladder to a volume 
of approximately 200 mL. At roughly this volume and above, stretch transduction 
begins to breach a threshold, triggering a shift in the reflex pathways. 
Filled State 
 Sensory afferents arriving at the sacral cord from mechanoreceptors 
within the detrusor convey the filled status upward to the thoracolumbar levels and 
outward to the inferior mesenteric ganglion and back to the detrusor. This begins 
the release from the relaxation state through the inhibition of adrenergic outflow 
and the elimination of hyperpolarizing outward potassium flux from myocytes.149 
The impulses conveying the filled status continue to ascend the cord to the pons 
and eventually to the cortex, as indicated by the succinct conscious message, “I 
have got to go.” The cortical integration and control bestow the ability to continue 
to hold past a certain threshold, as our decisions to hold are cofidied as increased 




simultaneous contraction of the external urethral sphincter. The cortical response 
to afferent input is the ultimate arbiter in the change from holding and filling to 
voiding, evidenced by the cystometrograms of patients under isoflurane 
anesthesia. Isoflurane prevents the conscious modulation of micturition, resulting 
in regular cycles of filling and voiding corresponding to the volume and pressure 
of the bladder as its status is integrated into a reflexive response. Without cortical 
input, the pontine storage center experiences reduced activation and increased 
inhibition from interneurons in the pons, indicating increased bladder pressure. 
This results in reduced sympathetic outflow from the thoracolumbar spinal cord, 
which favors contraction of the detrusor and relaxation of the internal urethral 
sphincter in males.149  
In the sacral cord, signals from the storage center produce reduced 
inhibition of parasympathetic outflow to the detrusor. Simultaneously, reduced 
inhibition and increased activation of the pontine micturition center produces 
descending efferent signals that travel to the spinal cord with synergistic effects: 
inhibiting adrenergic outflow in the thoracolumbar cord and stimulating 
parasympathetic signaling in the sacral cord. With a desire to empty, voiding 
occurs as the detrusor contracts and the external urethral sphincter relaxes under 







The specific aims of this paper are: 
1. To evaluate current information regarding the pathology of ketamine-
induced cystitis. 
2. To synthesize a more precise mechanistic approach for understanding 
ketamine-induced cystitis. 
3. To use this knowledge in guiding future research and developing effective 






KETAMINE-INDUCED CYSTITIS: LITERATURE REVIEW 
 
KETAMINE 
From its first synthesis in 1962, Ketamine received immediate attention for 
its anesthetic and dissociative properties and was quickly incorporated into 
veterinary and human surgeries.150,151 After U.S. Food and Drug Administration 
(FDA) approval in the 1970s and its success in the operating room, the purview of 
its use expanded, though off-label. Ketamine continues to garner a status rivalling 
a panacea amongst medical professionals. From chronic pain to treatment-
resistant psychological disorders, intravenous (IV) and, more recently, nasal 
ketamine provides hope and relief for a subsection of patients who border on 
hopeless.152  
Initial pharmacologic investigation of ketamine provided fledgling evidence 
of peripheral toxicity, with acute effects on the cardiovascular and respiratory 
systems including tachycardia, hypertension, and bradypnea.153 Chronic use has 
been associated with tolerance, dependence, neurotoxicity, hepatotoxicity, 
choledochal cysts, and urological pathologies.153–156 Urological pathologies 
associated with ketamine use include: ulcerative cystitis, hydronephrosis, and 
lower urinary tract symptoms (LUTS), with many of these disease processes 
stemming from an unknown instigator. With 26.6% of current and 50% of 




mechanism of urological toxicity as nasal ketamine gets introduced to patient 
populations who may require the drug for long-term treatment.157,158 
Ketamine is a stereoisomeric phenylcyclidine-derivative that is lipophilic and 
rapidly crosses the blood-brain barrier to bind to α-aminohydroxymethylisoxazole-
proprionic acid (AMPA), N-methyl-D-aspartate (NMDA), and opioid receptors in 
the nervous system to elicit dissociative, anti-depressive, and analgesic effects. 
Ketamine in the bloodstream is converted into norketamine by the Cytochrome P 
(CYP) system in the liver. Norketamine, an active metabolite, retains its ability to 
cross the blood-brain barrier, but binds less avidly to its array receptors. Both 
ketamine and norketamine are eventually hydroxylated and glucuronidated in 
preparation for excretion in the urine, though a majority of the metabolism and 
metabolomics of ketamine beyond this remain a mystery.150 Ketamine primarily 
functions centrally as a NMDA antagonist, inhibiting the release of glutamate, 
effectively muting neurons, and ostensibly leading to its psychotropic effects. The 
NMDA-hypothesis of ketamine provided a framework from which to understand 
some of the neurological and psychiatric effects, but its mechanism of action in 
depression has delivered a major hit to this theory. Hydroxynorketamine (HNK), a 
metabolite of ketamine, lacks the ability of its parent compound to bind to NMDA 
receptors, but still elicits rapid antidepressant effects in rats through a different 
glutamatergic signal cascade at the AMPA receptor.159 AMPA and NMDA are 
inotropic receptors present throughout the central and peripheral nervous system 




neuromodulation in the setting of overactive bladder syndrome capitalizes the 
presence of these receptors by antagonizing the release of glutamate, resulting in 
improvement of symptoms.162 Dysregulation of this signaling pathway has been 
implicated in a variety of movement and pain disorders, which may explain some 
of the LUTS associated with ketamine such as overactive bladder, reduced filling 
capacity, issues with voiding, etc.  
Ketamine, seen in Figure 3, has a chiral center at C2 and exists either as 
an R- or S-enantiomer. Racemic ketamine, the typical form of IV ketamine costs 
less than $1 a dose, whereas stereoselective esketamine costs $590-$895 a dose. 
Off-label usage of IV ketamine accrues the majority of its costs through 
professional supervision and IV placement, skyrocketing to several hundred 










Figure 3. Chemical structure and metabolism of ketamine. Ketamine exists as an 
enantiomer with its chiral center at C2. The actions of the CYP system in hepatic cells 




such as dehydronorketamine and hydroxyketamine, all of which find their way into urine. 
CYP = cytochrome P system. Figure taken from Ref. 163 (Peltoniemi et al., 2016). 
 
Esketamine received FDA approval as a nasal spray for TRD earlier this 
year and will be marketed by Janssen Pharmaceuticals as Spravato™.  
Esketamine, touted for its lack of psychotropic and dissociative effects, and its 
nasal delivery, offer few advantages over IV racemic ketamine, as only two of four 
phase III clinical trials of Spravato™ demonstrated an effect greater than 
placebo.164 The duration and dose provided during the Spravato™ trials, 
particularly TRANSFORM-3, complicate the issue further, as the trials lasted an 
average of 28 days with a starting dose of 28 mg of esketamine. The starting dose 
of 28 mg was quickly increased to 54 mg and 84 mg, with 64.5% of participants 
reaching the maximum daily dose by the completion of the trial. The little 
information about the dose-tolerance of esketamine and the long-term 
treatment/maintenance needed for patients with TRD emphasizes the need for 
understanding the effect of ketamine on the urinary system. A survey of ketamine 
usage divided recreational users into low-use, medium-use and high-use typical 
dose groups, with 31% reporting use of 0.125 g or less (low), 35% reporting use 
of 0.25 or 0.5 g (medium), and 34% reporting use of 1 g or more (high) during a 
typical session. These findings revealed significant associations between 




PATHOGENESIS OF KETAMINE-INDUCED CYSTITIS 
 Cystitis is an umbrella term referring to a group of non-neoplastic, 
inflammatory pathologies of the bladder generally presenting as LUTS. Ketamine-
induced cystitis (KIC) was defined as a clinical entity in 2007 and has since 
amassed the attention of a global health crisis. Approximately 26.2% of ketamine 
abusers suffer from LUTS and are predisposed to further urinary system damage 
such as hydronephrosis secondary to improper voiding and vesicoureteral reflux. 
Patients with KIC present with painful bladder syndrome, urge incontinence, 
dysuria, and urgency with absent bacterial cultures. Contact between ketamine or 
its metabolites and the urothelium result in submucosal edema, vascular ectasia, 
fibrosis, detrusor muscle inflammation, and fibrosis.165 Treatment for KIC ranges 
from cessation of use, oral and intravesical steroids, anticholinergics, oral non-
steroidal anti-inflammatory drugs (NSAIDs), intravesical Botox, and hyaluronic 
acid installation. Apart from the 51% of patients that report improvement in LUTS 
with cessation of use, many of these treatments lack significance or lasting 
effects.166 The lack of efficacy of proposed and studied interventions stems from 
an overriding theme through the literature: the inciting insult of KIC remains 
ambiguous and elusive. In the absence of a schematic in which to understand the 
pathophysiology of KIC, investigators and clinicians are relegated to treating 
symptoms rather than the first cause. The lack of consensus on the mechanism 
50 
results in a limited ability to identify this process in its nascent, reversible stages 
such that the first line approach of abstinence stands a greater chance of success. 
Ketamine-induced cystitis manifests itself in a fashion similar to interstitial 
cystitis, both pathologically and histologically, leading many to extrapolate 
processes from the later unto the former. Some of the shared symptomatology can 
be seen in Table 4. As more information accumulated, KIC became a distinct 
clinical entity warranting salvos of experiments that have a theoretical framework 
in which to understand this process. 
Table 4. Common Signs, Symptoms, and Complications of KIC 
This table shows the various symptoms and complications of ketamine-induced cystitis. 
KIC = ketamine-induced cystitis; VU = vesicoureteral reflux. Table taken from Ref. 167 
(Meng et al., 2013).  
Interstitial cystitis presents with suprapubic pain that is exacerbated by 
bladder filling and alleviated by emptying. Cystoscopic exam is typically 
unremarkable apart from petechial hemorrhaging of the urothelium. Other 
nonspecific symptoms include increased urinary frequency, urgency, dysuria, and 
hematuria. Interstitial cystitis is a cause of chronic pelvic pain syndrome and can 






reducing the size and compliance of the bladder. Polypoid cystitis results from 
inflammation of the bladder mucosa. Following the inflammation, fluid and cells 
leak into the compartment below the mucosa producing submucosal edema that 
throws the mucosa into swollen outcroppings that resemble papillary urothelial 
carcinoma.  
INTERSTITIAL FIBROSIS 
 Ketamine abuse is correlated with the development of LUTS including 
voiding frequency, urgency, urge incontinence, hematuria, dysuria, and pelvic 
pain.156,168,169 Clinical findings associated with the symptomatology include 
urothelial inflammation, a fibrotic and contracted bladder, vesicoureteral reflux, and 
sometimes hydronephrosis, leading to a hypothesis that ketamine and/or its 
metabolites are directly toxic to the urothelium resulting in an inflammatory 
response characterized by increased wall thickness and ECM deposition.170–172. 
Fibrosis can be defined as increased accumulation of ECM components, 
mainly collagen, and is a common feature of the pathophysiological adaptations of 
several organs, including the heart, lungs, liver, kidneys, and bladder.173,174 The 
ECM components are synthesized by fibroblasts in a process called fibrogenesis. 
Initially activated fibroblasts translocate to the injured tissue and commence wound 
repair. As the ECM components accumulate, pathological changes occur. In the 
bladder, this is represented by an irreversible decline in function and progression 
to renal insufficiency.175–177 Epithelial-mesenchymal transition (EMT) is an 




dedifferentiation of epithelial cells; these cells begin losing their phenotypic 
characteristics while acquiring features of mesenchyme.178 Loss of epithelial 
markers, such as E-cadherin (E-cad), cytokeratin, and ZO-1, co-occurs with the 
appearance of mesenchymal indicators, including vimentin, fibronectin, and  α-
smooth muscle actin (α-SMA) in EMT.179,180 The downregulation of E-cad functions 
as a regulatory step in EMT, as its expression is held in check by transcription 
factors like Snail, Slug, and Twist.181,182 Transforming growth factor β1 (TGF-β1) 
has been well established as a principle molecule involved in fibrosis and 
fibrogenesis. More recent evidence has suggested a potent ability to induce EMT. 
Mechanistically, TGF-β1 binds to type 2 TGF-β1 receptors, which then 
phosphorylate type 1 receptors.183,184 Downstream targets of activated type 1 
receptors include (S-Mothers Against Decapentaplegic) SMAD-dependent and 
MAPK-dependent transduction pathways.185  
Junpeng Wang and colleagues investigated the relationship between TGF-
β1 levels and ketamine-induced bladder fibrosis in a rat model. Sprague-Dawley 
rats were separated into four groups: control, ketamine, ketamine + TGF-β1 
inhibitor, and ketamine followed by a period of discontinuation. Bladders were 
removed for histology, immunohistochemistry (IHC), and immunofluorescence, 
while immortalized human urothelial cells, SV-HUC-1, were cultured and used to 
quantify TGF-β1 levels. By the end of 16 weeks, all ketamine treated rats 
developed voiding dysfunction and decreased bladder compliance, indicated by 




and decrease in bladder volume.186 Voiding dysfunction persisted despite 
abstinence, suggesting irreversible changes to bladder function. Histologically, 
ketamine exposure produced thinning of the urothelium and significantly increased 
collagen deposition in the muscle layers and these findings were unchanged 
following discontinuation of ketamine. Though the urothelium was thinning, it 
remained intact despite increased fibrosis, suggesting that fibrosis is not a product 
of ketamine’s traversal of the epithelium. The patency of the urothelium is also 
problematic for current explanations of ketamine-induced bladder overactivity. It 
was widely accepted that incomplete urothelial barrier function and the shedding 
of the urothelium contribute to bladder fibrosis and overactivity through the 
exposure/activation of mesenchymal cells to the potassium and sodium in urine.187 
E-cadherin is an important constituent of adherens junctions in epithelial 
cells and its presence is crucial for maintaining basic epithelial function and 
morphology.174,188,189 E-cad levels were significantly decreased in all ketamine 
groups relative to control, indicating the occurrence of EMT-associated bladder 
fibrosis. EMT is an important contributor to fibrogenesis and involves the 
downregulation of epithelia-specific proteins, like claudins and E-cadherin, 
eventually resulting in the loss of membrane polarity. Not only did ketamine 
significantly reduce E-cad expression and upregulate mesenchymal markers in 
urothelial cells, it also induced EMT as indicated by the appearance of E-
cadherin+/fibroblast specific protein 1(FSP1)+ and E-cad+/α-SMA+ urothelial 




treated rats and SV-HUC-1 cells exhibited elevated expression of genes involved 
in TGF-β signaling and increased TGF-β1 secretion, suggesting fibrosis is a TGF-
β mediated process. When ketamine was combined with a TGF-β1-inhibitor, SB-
505124, EMT and fibrosis were inhibited and TGF-β1 levels paralleled control.  
An increasing number of studies using rodent models have implicated 
cyclooxygenase 2 (COX-2) and inducible-nitric oxide synthase (iNOS) as the major 
molecular mediators of the inflammatory response observed in KIC.190,191 
Furthermore, ketamine is believed to significantly increase oxidative-stress 
through both mitochondrial- and ER- dependent pathways leading to caspase 
activation and eventual apoptosis. This apoptotic overdrive is believed to 
contribute to the recession, and eventual denudation, of the urothelium.192 Reports 
of increased purinergic signaling, demonstrated by upregulated P2XR-1 and 
downregulation of transgelin, may contribute to bladder overactivity.193,194 
Disruption of the cytoskeleton, evidenced by significantly decreased keratin-14, 
has been reported in Balb/c mice treated with 30 mg/kg/day of ketamine for eight 
weeks.195 After 20 weeks of treatment with 100 mg/kg/day ketamine, Balb/c mice 
demonstrated significant genetic alterations involved in the chronic wound healing 
response, suggesting an initial reversible stage of ketamine-induced fibrosis.196 
Expanding upon previous investigations into the fibrotic and inflammatory effects 
of ketamine, Shen Cheng-Huang and colleagues used cDNA microarrays to 
describe the altered gene expression associated with ketamine exposure at 100 




were corroborated with histological staining and scanning electron microscopy 
(SEM) imaging of urothelial morphology. Following one week of ketamine 
treatment, mice demonstrated reduced food intake that compounded over the 
following 19 weeks to produce a significant reduction in body weight relative to 
control. Microarray data indicated that long-term ketamine treatment alters 
expression of Ca2+-signaling components, such as PKC, large conductance Ca2+-
activated K (BK) channel, and CaM-kinase 2, which may be another instigator of 
detrusor overactivity in addition to increased purinergic signaling and decreased 
phosphorylated-transgelin (TAGLN). The BK channel is a heterooctamer 
consisting of four pore-forming units encoded by KCNMA1 and four regulatory 
units of the KCNMB4 moiety. Typically, voltage or calcium-gated, the BK channel 
is principally involved in the regulation of contraction by limiting the amplitude and 
duration of action potentials/phasic contractions in response to spikes in 
intracellular calcium. Ablation of the KCNMB4 gene in mice results in increased 
action potential frequency and excitability.197 Ketamine treatment was associated 
with a downregulation of KCNMB4, which may contribute to overactivity, while 
KCNMA1 and ryanodine receptor levels were unchanged when validated with real-
time quantitative polymerase chain reaction (RT-qPCR). Across all ketamine 
treated mice there was an upregulation of PKC and its downstream components. 
In vivo, PKC phosphorylates MYPT1 and inhibits MLCP, in turn increasing the 
amount of phosphorylated MLC and augmenting detrusor contraction.198 




resulting in reduced local Ca2+ spikes and Ca2+ reuptake into the SR providing 
another mechanism to elicit detrusor overactivity, as intracellular Ca2+ begins to 
accumulate and bring the muscle cells closer to threshold.199,200 Histologically, 
there was a scarcity of inflammatory infiltrate and minimal vascular congestion in 
the submucosa of all the ketamine-treated bladders. In humans, ketamine use 
induces an intense inflammatory response, therefore the lack of inflammation 
described in this study may represent species-specific inflammatory 
responses.201,202 Inspection of the urothelium demonstrated little alteration and 
patent barrier function which was supported by normal claudin and occludens 
expression as determined by RT-qPCR. Under SEM, the umbrella cell surface 
appeared eroded with a loss of scalloping of the apical membrane. Smoothing of 
the apical surface revealed well-defined borders equipped with functional 
adherens and tight junctions indicating the differential loss of uroplakins in the 
outer membrane leaflet of umbrella cell membrane.  
The fibrosis featured in ketamine use is associated with an abnormal wound 
healing response producing an irreversible decline in bladder function.166,196 
Mechanistically, this fibrotic state was assumed to stem from increased TGF-β 
expression leading to EMT, fibroblast activation, and ECM deposition, seen in both 
human patients and animal models. Consistent with a theory of TGF-β-mediated 
fibrosis, KIC patients report relief following treatment with anti-fibrotics or 
hyaluronic acid that inhibit TGF-β.203,204 RT-qPCR of ketamine treated mice had 




genes associated with ECM deposition and fibrosis were significantly upregulated, 
such as fibronectin (FN1), laminin (LAMC2), versican (VCAN), and angiotensin 
(AGT).205,206 Thus the observed collagen deposition and elaboration of 
submucosal folds in the ketamine treated bladders could not be explained by the 
current TGF-β-mediated mechanism and seems to hint at the presence of a TGF-
β-independent pathway to fibrosis.  
NERVE HYPERPLASIA 
Long-term ketamine use and abuse leads to the development of intractable 
bladder pain that appears neuropathic in origin. Ketamine induced bladder pain 
levels correspond with bladder thickening and contracture, as well as ulceration 
and shedding of the urothelium. The illicit drug status of ketamine convolutes any 
attempt to adequately define the patient population, as such estimates of 
prevalence and severity may be vastly underreported. Patients prescribed 
ketamine for chronic pain management differentially develop LUTS so it is 
reasonable to believe there is a highly susceptible subset of the population, but 
poor documentation of ketamine usage and its relation to functional and structural 
alterations in the bladder have hampered closer investigation.207,208 Anecdotally, 
the development of severe pain reinforces continued or elevated use of ketamine 
for its anesthetic properties producing a recursive loop of use and injury.157 
Histologically, KIC morphologically resembles urothelial carcinoma in-situ (CIS) 




lymphocytic infiltration and eosinophilia, and petechial hemorrhages accompanied 
by enlarged nuclei and disordered cell shape.156,169,209,210 
 In an effort to characterize the pathological features of KIC, Southgate et. 
al performed IHC on bladder specimens taken from patients suffering from 
clinically diagnosed KIC and interstitial cystitis (IC), another benign bladder 
syndrome that shares many features in presentation.211,212 Bladders from patients 
suffering from urge urinary incontinence secondary to either idiopathic detrusor 
overactivity (IDO) or stress-urinary incontinence (SUI) were used as controls. In 
this study, all KIC bladder sections demonstrated partial or full-thickness urothelial 
damage along with subepithelial neovascularization and edema of the underlying 
lamina propria with hematoxylin and eosin (H&E) staining.212 Most intriguingly, KIC 
bladder sections exhibited prominent peripheral nerve fascicles enveloped in well-
defined perineuriums throughout the lamina propria under H&E. These fascicles 
were positive for neurofilament protein (NFP), nerve growth factor receptor 
(NGFR), and S100 when examined for immunofluorescence. Additionally, the 
hypertrophic fascicles displayed a predominant Schwannian features, while their 
perineuriums displayed NGFR and epithelial membrane antigen (EMA). Each KIC 
bladder specimen was replete with NFP+ nerve fibers throughout the lamina 
propria, encroaching upon but not traversing the basement membrane of the 
urothelium. Normally, NGFR is confined to the blood vessel walls, interstitial cells, 
and peripheral nerve fascicles; following chronic ketamine use there is an intense 




lamina propria resemble myofibroblasts in morphology but are α-SMA negative. 
Only two of ten control bladders (one IDO and one SUI) and one of eleven of the 
interstitial cystitis (IC) samples shared NFP staining in the lamina propria. There 
were no neuroma-like lesions in any of the controls or IDO/SUI samples, therefore 
the reactionary neurogenesis is a distinct feature in the pathology of KIC. The 
severe bladder pain associated with KIC likely stems from the stromal nerve 
hyperplasia, neuroma-like lesions in the bladder wall, and expanded NGFR 
expression, but whether this occurs as a direct result of ketamine exposure is 
unclear at present. The determination of the origins of ketamine-associated nerve 
hyperplasia is complicated by ketamine’s profound effect on the production of 
brain-derived neurotrophic factor.213 It has been reported that the serum BDNF 
concentration of chronic ketamine users is twice that of controls and could be an 
instigator of nerve growth. Previous studies have reported increased cell division 
in the urothelium of KIC models, as indicated by elevated Ki67 levels. Taken with 
the expansion of NGFR, the urothelium takes on a wound-healing phenotype 
during chronic ketamine exposure. The juxtaposition of regions of desquamated 
urothelium adjacent to areas with intact barrier function and normal uroplakin 
expression appears consistent with a wound-healing response, but whether this is 
direct cytotoxicity from ketamine or one of its metabolites is unknown.209 Ketamine 




AMPA receptors, despite being classified as a NMDA receptor antagonist, further 
miring the mechanism of KIC.214  
Extending previous research into ketamine-associated nerve hyperplasia 
and TGF-β-mediated fibrosis, Jia-Fong Jhang interrogated the effect of ketamine 
on the expression of various neurotrophins, cellular proliferation kinases, and 
elements of the TGF-β signaling cascade in the bladders of patients with severe 
and mild KIC. Determination of severity was based on upper urinary tract 
involvement, intractable bladder pain despite prior conservative management, and 
urodynamic measurements of maximal bladder capacity (MBC) and cystometric 
bladder capacity (CBC). Patients with a CBC of <300 mL and an MBC of <100 mL 
upon cystoscopic hydrodistension with 80 cm of water, indicative of significant 
bladder contracture, were placed in the severe KIC group.215 The use of specimens 
from patients with localized bladder cancer as controls represents a significant 
drawback to this study, as these samples may not be genetically intact. Despite 
this, great care was taken to correlate patient symptoms with corresponding 
changes in bladder histology and protein expression. The results address an 
obvious mechanistic gap in our understanding of KIC. Over the course of 
conservative management, patients with mild KIC experienced significant 
improvement in pain symptoms with conservative management, evinced by visual 
analogue scales (VAS), but retained issues with urinary frequency and urgency. 
Conservative management was defined as the gambit of cessation, intravesical 




anticholinergics, steroids, and NSAIDs. Fourteen of sixteen severe KIC patients 
experienced little to no relief during treatment, while all severe KIC patients 
exhibited significantly smaller CBC and MBC during urodynamic evaluation and 
significantly higher VAS scores. Confirming previous reports of nerve hyperplasia, 
nerve growth factor (NGF), and S100, staining of severe KIC bladder sections 
revealed an intense permeation through all tissue layers, significantly increased 
relative to both control and mild KIC samples, along with urothelial denudation, 
inflammatory infiltrate, proliferation of submucosal folds.215 The intensity of S100 
staining in sections taken from severe KIC patients was significantly correlated 
with increased VAS scores and longer ketamine use, and inversely proportional to 
bladder capacity as detected by MBC and CBC. In order to better characterize the 
resultant nerve hyperplasia, levels of neurotrophins and cell proliferation kinase, 
assessed by western blot, were compared across groups based on KIC severity, 
VAS scores, and intensity of NGF and S100 staining. When comparing across 
levels of KIC severity, there were significantly elevated levels of neurotrophins 
assessed by growth associated protein-43 (GAP-43) and BDNF, and cell 
proliferation kinases and mediators including tropomyosin receptor kinase A 
(TrkA), TGF-β, phosphorylated glycogen synthase kinase 3β (p-GSK-3β), p-Akt, 
and phosphorylated extracellular signal-regulated kinase (p-ERK) when compared 
with mild KIC patients and control. Appraisal based on intensity of S-100 staining 
depicted significantly higher levels of the proteins, except GAP-43 and TGF-β. 




neurotrophins and cell proliferation kinases apart from GAP-43, BDNF, and p-
GSK-3β. The levels of neurotrophins, GAP-43, NGF, and BDNF, in samples from 
severe KIC patients were significantly, or nearly so, correlated with reduced 
bladder capacity, increased pain levels, duration of use, and other clinical 
symptoms.215 Neurotrophin levels in severe KIC patients were significantly 
correlated with TGF-β, a known instigator of ketamine-induced bladder fibrosis. 
NGF, apart from its role in neural development, can stimulate tissue fibrosis and 
repair, whereas TGF-β has been shown to potentiate NGF signaling after 
injury.216,217 Taken as a whole, it appears, at least in chronic and severe cases, 
that elevated serum and urine neurotrophins elicited by ketamine can produce the 
main clinical manifestations associated with KIC: nerve hyperplasia, nerve 
hypersensitivity, bladder overactivity, tissue fibrosis, and bladder contracture. 
Intriguingly, there was no significant difference in protein levels across all indices 
of interest between mild KIC patients and control, despite exhibiting symptoms. 
The reason remains unclear as to whether this was a result of unseen genetic 
abnormalities in the control samples taken from patients with invasive yet localized 
bladder cancer or a result of neurotrophins that elaborate an initial injury elicited 
by ketamine exposure given a sufficient duration of use.  
APOPTOSIS 
The preponderance of urothelial damage in KIC led many to believe that 
ketamine, or one of its metabolites, is directly cytotoxic at sufficient doses. Dose-




animal models, human samples, and urothelial cell culture reinforcing ketamine’s 
toxic potential. All indications point to ER- and mitochondria-mediated upticks in 
oxidative stress that trigger caspase activation and cell death. The apoptotic 
pathway allows controlled cell-death in which immunogenic and volatile 
compounds are safely packaged in membrane prior to cellular dissolution, 
preventing juxtacellular damage, inflammation, and an immune response. Though 
caspase-mediated apoptosis and increased oxidative stress have been 
established in cases of KIC, it is hard to deny the existence of an immune response 
in severe or late-stage samples that exhibit lymphocytic infiltration, edema, and 
diffuse eosinophilia. It would appear then that either this apoptosis is dysregulated 
and incomplete or it occurs in concert with necrotic and necroptotic cell death. Liu 
Keh-Min and colleagues scrutinized the apoptotic response of the urothelium of 
female Sprague-Dawley (SD) rats to 25 mg/kg/day ketamine over a course of two 
or four weeks. Taking a holistic approach, the investigators assessed bladder and 
renal function, urine metabolites, detrusor contractility, cell viability, urothelial 
integrity, and the levels of proteins and mRNA associated with apoptosis and 
oxidative stress. Detrusor muscle strips from rats treated for four weeks had 
significantly stronger contractile responses than control or two-week treated strips 
when stimulated by electric field stimulation (EFS) at all frequencies tested, 20 µm 
carbachol, and 120 mM KCl. Relative to control, the rats treated with ketamine for 
four weeks had significantly increased bladder weight and creatinine clearance 




treatment groups demonstrated significantly increased voiding frequency, peak 
micturition pressure, and elevated urine protein/creatinine ratios, all at or below a 
level of p < 0.05. Ketamine and norketamine were undetectable in serum, but 
reached concentrations of about 1.5 µg/mL and about 32 µg/mL in urine, 
respectively.218 Histologically, ketamine treated rat bladder sections were 
characterized by a thinning urothelium with increased interstitial fibrosis at two 
weeks that progressed to ulceration of the mucosa and full-thickness fibrosis at 
four weeks. Two independent histologists evaluated the location and intensity of 
junction-associated proteins E-cad, claudin-4, and ZO-1, and they concluded that 
the barrier function was likely disrupted. The level of tight junction ZO-1 and 
claudin-4 staining was significantly reduced in both ketamine treated groups 
relative to control and was accompanied by a sparsity of umbrella cell markers 
such as uroplakinIII. Terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) assays were used to quantify the proportion of apoptotic cells relative to 
the total present in tissue sections. Both ketamine treated groups demonstrated 
significantly increased numbers of apoptotic cells in all tissue layers, reaching 
17.2% in the urothelium, 34.4% in the suburothelium, 28.6% in the detrusor 
muscle, and 25.3% in the interstitium of the bladders sections taken from rats 
treated for 28 days.218 Further elucidating the apoptotic mechanism, staining and 
western blots for apoptosis- and ER stress-associated markers were performed. 
Anti-apoptotic protein, B-cell lymphoma (Bcl-2), levels were significantly reduced 




experienced a significant increase in the proapoptotic proteins: cytochrome C, 
caspases-3, -8, and -9, and poly-ADP ribose polymerase (PARP). ER-stress, 
evaluated through markers of the unfolded protein response including glucose 
regulated protein-78 (GRP78), CCAAT-enhancer-binding protein homologous 
protein (CHOP), and caspase-12, appeared to correlate with duration of ketamine 
exposure, reaching significance in both ketamine groups relative to control. 
Additionally, ketamine treatment was associated with significant elevation of 
oxidative stress markers, dinitrophenol (DNP) and nitrotyrosine, and the depletion 
of antioxidant enzymes: superoxide dismutase (SOD) and catalase. Synthesizing 
these results into a coherent mechanism, it appears that lumenal 
ketamine/norketamine exposure of significant duration either directly or indirectly 
alters mitochondrial function of cells in the urothelium. This dysregulation, 
evidenced by upticks in expression of the respiratory chain enzymes in both 
treatment groups, generates increased reactive oxygen species (ROS) as the 
mitochondria struggle to keep up with the ATP demands of an increasingly 
hyperactive bladder and electrons begin to leak from the enzyme complexes, 
pulled by the electrochemical gradient.219,220 Increased ROS production, 
overpowers normal antioxidant mechanisms and begin to damage cellular 
constituents, such as junctional proteins, as superoxides and peroxides 
accumulate instead of non-reactive by-products of water and molecular oxygen.218 
In response, the ER intensifies protein production, but improper folding and 




to the production of proapoptotic GRP78 and CHOP. These apoptotic signals are 
propagated to the mitochondria via CHOP and caspase-8 mediated B-cell 
receptor-associated protein-31 (Bap31) cleavage. Eventually signals from the ER 
and those internally generated by mitochondrial stress activate the mitochondrial 
permeability transition pore (MPTP) which releases sequestered cytochrome c into 
the cytoplasm. The resultant formation of the apoptosome with caspase-9 triggers 
the activation of caspase-3 and the execution of the cell. Altered junction protein 
expression, as demonstrated by the disrupted apical staining and cytoplasmic 
sequestration of ZO-1, E-cad, and claudin-4 in the ketamine-exposed groups 
compounds with apoptosis to produce disrupted barrier function. Once the 
urothelial barrier is breached, volatile compounds, including ketamine and 
norketamine, amplify the apoptotic process and produce an inflammatory 
response that spirals into the established KIC phenotype, spreading through all 
tissue layers. Though a robust indicator of a potential mechanism of KIC, the study 
fails to identify the cause of mitochondrial dysregulation and the duration of 
ketamine exposure before examination makes it difficult to discern ketamine’s 
effect from resultant inflammatory and wound-healing responses.  
In 2016, Baker and his co-investigators answered the remaining questions 
regarding the mechanism of ketamine-induced apoptosis. NMDAR-mediated 
apoptosis by antagonists like ketamine had been previously demonstrated in in 
vivo studies of rat and primate cortical neurons and NMDAR have been reported 




occurring in ketamine-exposed urothelial cells.221–223 To determine whether 
ketamine-induced urothelial apoptosis resulted from NMDAR-mediated 
antagonism or an unknown process, Baker interrogated the effects of various 
concentrations of ketamine on organ cultures of human ureteric tissue and cell-
lines of normal human urothelial (NHU) cells. Direct exposure of ureter organ 
cultures to 3 mmol/L ketamine for 72 hours produced a general thinning of the 
urothelium throughout the culture with cells demonstrating pyknotic nuclei and 
karyorrhexis under H&E.224 Dose-dependent effects of ketamine on NHU cells 
were quantified over a 6-day time course. Ketamine reproducibly induced a growth 
inhibitory effect at a concentration >0.3 mmol/L, a cytostatic effect at a 
concentration of 1 mmol/L, and a cytotoxic effect at a concentration >1 mmol/L.224 
Western blots were performed on whole cell lysates and enriched cytoplasmic and 
mitochondrial fractions of NHU cells exposed to 3 mmol/L ketamine after 24 hours 
and over the course of 2 hours. Cytoplasmic levels of cytochrome, reported via 
densitometry, jumped two-fold after just one day of exposure. Additionally there 
was a rapid depletion of p-Akt and p-ERK over the course of 2 hours, 
consequentially releasing p-GSK-3β from inhibition, and presumably eliciting 
apoptosis.224 Alamar blue reduction assays, serving as a proxy for cell viability, 
performed on NHU cells exposed to concentrations of 1.5–3 mmol/L ketamine 
depicted a significant and dose-dependent toxicity relative to control that could be 
attenuated by treatment with 10 µmol/L of a p-GSK-3β inhibitor.224 There was a 




cells upon addition of 1–3 µmol/L of cyclosporin A, which inhibits MPTP activation 
and apoptosis. Though significantly elevated active-caspases were detected on 
western blot, the resultant apoptosis could not be explained by NMDAR-mediated 
antagonism as GRIN transcripts for the NMDA receptor were absent upon RT-
PCR in both NHU cells and freshly isolated urothelium.224 Despite the absence of 
its preeminent binding partner, 1 mmol/L ketamine provoked a transient increase 
in cytosolic calcium that was comparable to stimulation with 50 µmol/L of ATP. The 
amplitude and duration of the Ca2+ transient was concentration-dependent and 
associated with perceived toxicity. One-minute exposure to concentrations of 1 
mmol/L ketamine and below prompted a significant elevation of intracellular Ca2+ 
lasting roughly one and a half minutes. The same exposure to 3 mmol/L ketamine 
elicited the same magnitude of Ca2+ elevation, but its effect endured beyond ten 
minutes. The Ca2+ transient was unchanged despite starving the NHU cells of 
extracellular Ca2+ and was eliminated upon addition of 2-aminoethoxydiphenyl 
borate (2-APB), an IP3-receptor inhibitor; proving release from the ER. Probing for 
its source, the researchers co-treated the NHU cells with an ecto-ATPase and a 
purinergic receptor inhibitor. Co-treatment of 1 mmol/L ketamine with an ecto-
ATPase inhibitor exacerbated both the amplitude and duration of the transient 
compared to cells administered ketamine only. Conversely, inhibition of P2Y 
receptors with pyridoxal-phosphate-azophenyl-disulfonate (PPADS) eliminated 
the response, but this inhibition was overcome with 3 mmol/L ketamine exposure. 




release into the extracellular space that is able to bind to P2Y receptors prompting 
IP3-mediated Ca2+ release from the ER and eventual urothelial cell death. To 
evaluate the link between ketamine-induced Ca2+ -release and observed toxicity, 
mitochondrial physiology was monitored during treatment with ketamine and 
various inhibitors. Tetramethylrhodamine (TMRM) –labeling of NHU cells was used 
to validate hyperpolarization of the mitochondrial membrane potential elicited by 3 
mmol/L ketamine, as elevated cytosolic Ca2+ alters mitochondrial function while 
they struggle to meet rising ATP-demands. Following a 48-hour exposure to 3 
mmol/L ketamine, NHU cells had already significantly depleted their cellular stores 
of ATP, decreasing by nearly 23%.224 After a 48hr incubation with 3mmol/L 
ketamine, the resting mitochondrial oxygen consumption rate (OCR) of NHU cells 
fell well below those of the control. Addition of oligomycin, an ATP-synthase 
inhibitor, depressed mitochondrial OCR in both ketamine-treatment and control 
NHU cells in proportion to their current levels of ATP production, though the effect 
was more striking in the control. Administration of the mitochondrial uncoupling 
agent, carbonylcyanide-4-trifluoromethoxyphenylhydrazone (FCCP), abolishes 
the proton-motive force across the inner mitochondrial membrane and establishes 
a maximum OCR as all mitochondrial efforts are directed at rectifying the ever-
leaking gradient. Ketamine-treated NHU cells experienced no rebound in OCR 
following administration of FCCP, whereas those of controls increased nearly 5-
fold.224 The effects of ATP-synthase inhibition and uncoupling agents on the OCR 




allocated the majority of increasingly scarce resources toward retaining a proton 
gradient in response to long-term ketamine-induced hyperpolarization. Not only 
were ketamine-exposed NHU cells producing less ATP, but they were effectively 
consuming it to run ATP-synthase in reverse, serving as another direct drain on 
cellular ATP levels.224 Activation of p-GSK-3β, caused by reduced Akt and ERK 
inhibition, adds to increasing mitochondrial stress to breach the threshold of the 
MPTP and trigger apoptosis. The sum of the investigators’ efforts elucidated the 
mechanism seen in Figure 4. Though criticisms abound from the use of cultured 
cells and tissues rather than in vivo methodologies, this study provided an 
explanation for some of the progressive erosion of the mucosa from the lumen 














Figure 4. Mechanism of ketamine-induced apoptosis. In this proposed model, 
ketamine binds to a “mystery” receptor, though evidence indicates this is likely mediated 
by adrenergic, NMDA, or AMPA receptors. This binding results in the release of ATP, 
which is subsequently metabolized by extracellular ATPases. These metabolites bind to 
purinergic receptors, eliciting G-protein activation and downstream production of IP3 and 
Ca2+ release from the ER. Depending on dose, ketamine sustains this Ca2+ release, 
eventually stressing the mitochondria and ER by altering membrane potential and protein 
function. Ultimately, the MPTP opens, and caspase-mediated apoptosis occurs. ATP = 
adenosine triphosphate; MPTP = mitochondrial permeability transition pore. Figure taken 
from Ref. 224 (Baker et al., 2016).  
 
MICROVASCULAR INJURY  
Microvascular injury and inflammatory cell infiltration are commonly 
reported in tissue sections taken from severe KIC patients and animal models of 
KIC. Ranging from apparent vessel congestion to fibrinoid vascular necrosis, it 




injury and subsequent remodeling leading to disrupted circulation and hypoxia. To 
deduce whether this was a direct effect of ketamine or a downstream effect of 
ketamine-induced inflammation, bladder specimens were taken from diagnosed 
KIC patients and matched-controls, examined for pathology, and performed 
immunoreactivity for NMDAR1, FSP-1, and endothelial cell marker cluster of 
differentiation-31 (CD-31). Previous studies have demonstrated the existence of 
NMDA receptors throughout the urogenital tract of human males and rats225; 
NMDAR1 in the brain controls tissue plasminogen activator (tPA)-induced 
signaling that mediates translocation of monocytes across the blood brain 
barrier.226 Chu et al proposed that ketamine might elicit microvascular changes 
and subsequent endothelial injury that compromises the microcirculation of the KIC 
bladder.168 In keeping with this idea, gross hematuria is a frequently reported 
symptom in late-stage ketamine abusers and corresponds with increasing vascular 
distribution that can be witnessed on cystoscopy.169,171,227 KIC patients included in 
this study averaged 3.5 years duration of use and reported LUTS after 1.5 years 
of use. Common radiological abnormalities found in this sample included 
vesicoureteral reflux, hydronephrosis, and ureteral stenosis. H&E staining of KIC 
bladder biopsies all shared submucosal inflammation, enlarged vascular walls, 
urothelial insult, and eosinophilic infiltration in stark contrast to those of control 
specimens.228 Affected medium and small vessels examined under transmission 
electron microscopy (TEM) contained endothelial cells with elaborated basement 




control and, to a lesser extent, KIC patients co-expressed NMDAR1 and CD-31 
within their small and medium arterioles; suggestive of a direct effect of ketamine 
on endothelial dysfunction and vascular remodelling.228 Endothelial cells have the 
ability to de-differentiate into a more mesenchymal phenotype in response to 
particular growth factors and inflammatory mediators in a process called 
endothelial-mesenchymal transition, (EndMT). After assuming mesenchymal 
markers, these cells can activate fibroblasts and myofibroblasts, initiating an 
established cascade of pathogenic tissue fibrosis.178,180,229 To confirm the 
plausibility of NMDAR-mediated vascular fibrosis, the investigators quantified the 
number of endothelial cells with co-localized CD-31 and FSP-1, markers of 
EndMT, across sections from control and KIC specimens, finding the count to be 
significantly elevated in those of the latter.228 In all, they conclude that long-term 
ketamine use could induce pathogenic vascular remodeling and contribute to the 
progression of KIC. The extent, or existence, of this contribution remains to be 
determined, but seems unlikely. Levels of NMDAR1 in the vasculature of KIC 
patients were much lower than control reflecting either down-regulation of 
receptors in response to long-term ketamine exposure or a chronic wound-healing 
reaction involving de-differentiation, differential receptor expression, and 
endothelial injury. Furthermore, affected KIC vessels tended to be circumscribed 
by eosinophil and mast cell infiltration suggesting that vascular compromise was 
mediated by an immunoglobulin E (IgE) chronic inflammatory response. 




dominant inflammatory pathways, producing vascular remodeling and fibrosis in 
the lungs of asthmatics, so it is not unreasonable to assume this occurs as a 
secondary effect. Groups of researchers still pined for a mechanism to directly link 
NMDAR, and therefore ketamine, to EndMT and pathogenic fibrosis; their efforts 
furnished two potential pathways, one traditionally associated with inflammation 
and another with metabolic changes and cell survival. The mammalian target of 
rapamycin (mTOR) is an established participant in the signaling required for 
vascular remodeling and can be activated directly by the association of ketamine 
with the NMDA receptor in neurons of the prefrontal cortex and PC-12 cells from 
pheochromocytoma.230–232  
In 2016, Lin et al. demonstrated that ketamine exposure activated the 
mTOR pathway and significantly upregulated its end-products in tissue sections 
taken from long-term abusers and cultured human bladder microvascular 
endothelial cells (HBdMECs). The KIC patients enrolled in this study averaged a 
mean intake of 3.4 g/day over a course of 3.5 years with onset of LUTS following 
2 years of use. Biopsies taken from these patients were hypervascular with 
prominent inflammatory cell presence extending into the submucosa, notable for 
localization of eosinophilic cells to the periphery of vessels. S6RP, an end-product 
of the mTOR pathway, intensely stained the endothelial cells of KIC sections while 
scarce in the mucosa.233 Cultured HBdMECs had significantly increased levels of 
phosphorylated, active mTOR in as little as 30 minutes after exposure to 100 µM 




phosphorylated ribosomal protein S6 kinase β-1 (p70S6K), another downstream 
mTOR mediator, after 6 hours of incubation.233 Ketamine-induced mTOR 
activation corresponded with the assumption of mesenchymal markers associated 
with EndMT as the treated HBdMECs  co-localized FSP1 and CD31 in an effect 
that was tempered by the mTOR inhibitor and macrolide antibiotic, rapamycin.233 
As noted previously, EndMT has emerged as a major contributor to pathogenic 
fibrosis via activation of fibroblasts and myofibroblasts. NMDAR activation can also 
mediate an upregulation of type I collagen through phosphoinositide-3 kinase 
(PI3K) and AKT signaling adding to the profibrotic milieu.234,235 Nuclear factor-κβ 
(NF-κβ) are a family of dimeric protein complexes that when dissociated act as 
transcription factors. In the inactive state, NF-κβ are snared within the cytoplasm 
bound to inhibitors of κβ (Iκβ).236,237 Signal transduction, beginning at GPCRs, 
stimulate the phosphorylation of Iκβs by Iκβ-kinase. The added phosphates serve 
as sites for ubiquitination and subsequent proteosomal degradation, liberating the 
NF-κβ subunits. Unconstrained, these factors translocate to the nucleus and enact 
rapid alterations in gene expression. One such altered gene is cyclooxygenase-2 
(COX-2) whose interactions with NF-κβ were determined based off significantly 
shared sequence homology between the NF-κβ binding site and the promoter of 
COX-2.238 COX-2 is an inducible inflammatory mediator activated in response to 
injurious stimuli, cytokines, and endotoxins that occasion the production and 
release of prostanoids.239,240 Prostanoid production can contribute to bladder 




particular, prostaglandin E2 (PGE2) can invoke altered micturition patterns by 
sensitizing afferent neurons.241,242 In the bladder, COX-2 expression in stromal 
cells can serve as a prognostic biomarker of urothelial cancer and its levels 
intensify in animal models of chemically-induced hemorrhagic cystitis.243,244 The 
COX-2 promoter sequence contains several other response elements including 
one for cyclic adenosine monophosphate (cAMP).245 Yung-Shun Juan and 
colleagues suggested a role for NF-κβ and COX-2 in the inflammatory progression 
of KIC after examining the effect of ketamine and norketamine on SD rats over 28 
days on cultured primary urothelial cells and on human bladder carcinoma (J82) 
cells. Following 4 weeks of daily intraperitoneal (IP) injection 25 mg/kg ketamine, 
rats portrayed detrusor hyperactivity with significantly elevated numbers of voiding 
and non-voiding contractions. Coadministration of 10 mg/kg of the COX-2 inhibitor, 
parecoxib, normalized detrusor activity and ameliorated non-voiding contractions 
when compared to the ketamine and control groups. Masson’s trichrome staining 
for level of fibrosis was magnified in the ketamine-treated rats with diffuse 
interstitial fibrosis and collagen bundles extending between the components of the 
detrusor smooth muscle. The urothelium of these rats was described as ulcerated 
and significantly thinner than those of controls. Parecoxib effectively 
downregulated this fibrotic response and preserved the integrity and stratifications 
of the urothelium. Ketamine-exposed rats co-expressed COX-2 and NF-κβ within 
their urothelium with subepithelial activation of macrophages, substantiated by co-




with NF-κβ levels in ketamine bladders, but there was no double-labelling of the 
proteins when ketamine was coadministered with parecoxib, suggesting that 
synthesis of these proteins occurs during the inflammatory process of KIC. Primary 
urothelial cell cultures were utilized to assess NF-κβ levels and localization within 
cells. Ketamine treated cells contained diffuse NF-κβ and COX-2 staining with the 
cytoplasm and nucleus, while those treated with ketamine and parecoxib were 
delicately stained with NF-κβp65 in the cytoplasm only, therefore parecoxib 
prevented the translocation of NF-κβ subunits and subsequent altered gene 
expression associated with ketamine exposure. Western blots of cytoplasmic and 
nuclear fractions of ketamine-incubated urothelial cells were significantly enriched 
in NF-κβ compared to both controls and the parecoxib groups. To validate the 
ability of NF-κ to alter COX-2 gene expression, the investigators transfected 
cultured J82 cells with COX-2 promoter plasmids of different length conjugated to 
luciferase. NF-κβ was able to directly interact with COX-2 promoter sequence at 
two sites, both upstream of cAMP response element. Promoter deletion assays 
were unable to determine the exact location of these binding sites but placed them 
between -918 and -250 bp. Overall, NF-κβ appears to play a key role in ketamine-
induced COX-2 activation and subsequent inflammation 
 ALTERED PROTEIN AND GENE EXPRESSION 
Early stage KIC morphologically resembles other benign bladder 
syndromes such as IC and painful bladder syndrome (PBS) with relatively 




early stage KIC patients who remain in the reversible stages of their injury and may 
significantly benefit from conservative management. Despite shared initial 
pathological features, many treatments for other benign bladder disorders fail to 
improve symptoms in KIC patients, particularly late-stage patients. In order to 
develop diagnostic markers and effective treatments KIC needs to be better 
characterized, an effort that begins with proteomic assays.  
Apart from its barrier function, the urothelium expresses a variety of 
receptors allowing it to function as a sensory web to transduce signals from the 
lumen to the submucosa. Past animal models of KIC have evinced abnormal 
sensory protein expression including upregulated P2X receptors, while KIC 
bladder biopsies show elevated inflammatory and sensory protein 
expression.201,246 Across 29 KIC bladder biopsies, Yao Chou Tsai and Lori Birder 
found consistently elevated levels of apoptosis and mast cell tryptase, whereas E-
cadherin and ZO-1 were significantly downregulated and corresponded to an 
ulcerated and tapered urothelium.247 Their western blots comparing homogenized 
tissue specimens from 16 KIC bladders demonstrated significantly elevated M3 
and β3-adrenergic receptors (β3-ARs) compared with the bladder lysate of 
controls.247 M3 receptors are primarily responsible for bladder contraction in 
humans as they bind ACh and trigger detrusor depolarization; their upregulation 
could reasonably increase detrusor activity. β3-ARs mediate detrusor relaxation 
but their contribution to voiding dysfunction in the KIC bladder remains unclear. A 




comparing the bladder lysates of male SD rats that had received daily IP injections 
of normal saline or 50 mg/kg ketamine for 16 weeks.193 After two dimensional 
difference gel electrophoresis, the significant protein spots were ablated from the 
gels and sent for mass spectroscopy and Mascot protein identification; the fold-
change in expression relative to control of several notable proteins are depicted in 
Table 5. Of particular interest were the significant alterations in levels of 
phosphorylated and non-phosphorylated transgelin.193 TAGLN is a 22-kDa actin 
binding protein expressed in the smooth muscle cells of the uterus, prostate, and 
bladder.248–250 The onset of its expression serves as marker of nascent smooth 
muscle cell differentiation.251 Phosphorylation of transgelin reduces its affinity for 
actin leading to its release, potentially freeing up more active sites for myosin 
interaction. PKC can phosphorylate transgelin and inhibit its actin binding in vitro, 
whereas PFTK1 in hepatocarcinoma accomplishes this same effect to augment 
cell motility.252 Downregulation of non-phosphorylated transgelin has been 
associated with decreased bladder contractility in rat models of chronic bladder 
irritation and bladder outlet obstruction.253,254 The proteomic assays used in this 
study may be confounded as a result of duration, as it is hard to tease out whether 
these protein alterations are ketamine- or inflammatory-mediated. To accomplish 
this, investigations would have to go deeper and more immediate to evaluate 
altered gene expression in the burgeoning stages of KIC. Cheng-Huang Shen and 
his colleagues furnished this mechanistic gap, more by luck than intention, while 




course of daily IP administration of either 30 mg/kg ketamine or normal saline.195 
Histological sections of the ketamine-treated rat bladders had no discernible 
pathology relative to control yet gene expression and voiding dynamics differed 
markedly.195 Without inflammatory cell infiltrate or obvious urothelial defect, these 
genetic alterations must mediate the transition to blatant pathology. Listed in Table 
5, ketamine significantly altered the expression of genes involved in cell structure 
and adhesion. The majority of alterations occurred in one protein family: keratin. 
Keratins are fibrous intermediate filaments that are integral components of the 
cytoskeleton of epithelial cells. Though ubiquitously expressed in the urothelium, 
the individual strata can be identified based off keratin isoforms. Keratin-20 is 
localized to the umbrella cells, while intermediate and basal layers prefer the 
keratin-14 flavor.255 In the subapical strata, keratin-14 forms heterodimers with 
keratin-5 that polymerize into 10-nm-thick intermediate filaments that can arbitrate 
cell adhesion. Mutations to these genes results in a genetic variant of 
epidermolysis, epidermolysis bullosa simplex, whose characteristic lesions are 
accompanied by epithelial fragility in the genitourinary tract, voiding difficulties, and 
urinary retention.256,257 Both keratin-14 and keratin-5 were significantly 
downregulated compared with controls, whereas keratin-20, a prognostic marker 
of urothelial carcinoma, had levels that skyrocketed.258 Alterations in keratin 
expression may represent the transition point between reversible and irreversible 
pathology and could potentially serve as a diagnostic test for KIC. In cell-cell 




desmosomes and hemidesmosomes to impart epithelial integrity. In the 
urothelium, hemidesmosomes are typically expressed in the basal cell layer with 
sparse appearance in the intermediate cells causing re-categorization of 
urothelium from pseudostratified, and transitional, to stratified squamous. 
Hemidesmosomes tether keratin filaments to the basement membrane through 
plectin plaques and cellular adhesion molecules (CAMs), such as α6β4 integrin.259 
In the ketamine treated mice, α6 and β4 integrin gene expression were 
downregulated. Downregulation of integrins and alterations in keratin expression 
may serve to indicate the collapse of hemidesmosomes as the urothelium begins 
to denude. In addition, ketamine treatment was associated with a significant 
downregulation of claudin-1, suggesting that the resistive value of the urothelium 













T-kininogen 2 SD Rat Protein 50 mg/kg 16 wks 5.12 
T-kininogen 1 - - - - 8.34 
Plastin-2 - - - - 10.2 
Putative protein - - - - 11.7 
ATP-citrate synthase - - - - 10.6 
Actin, aortic smooth 
muscle 
- - - - 11.3 
Actin, gamma-enteric 
smooth muscle 
- - - - 10 
pTransgelin - - - - 8.12 
Endoplasmin - - - - -10.2 
Keratin type I - - - - -7.22 
Lamin-A/C - - - - -5.22 
Integrin-α6 - - - - 41.7 
Integrin-β4 - - - - -7.9 
Claudin-1 - - - - -12.5 
Keratin 20 - - - - 20.2 




Gene  4 wks 31.3 
Transthyretin - - - - 50.3 
TLR-12 - - - - 107.3 
Fucosyl-transferase 9 - - - - 37.1 
IL-33 - - - - -49.7 
Neuregulin 1 - - - - -42.8 
Metallothionein 2 - - - - -36.4 
Keratin 13 - - - - 29.9 
Keratin 14 - - - - -44.4 
Keratin 23 - - - - 16.6 
Keratin 78 - - - - -31 
Keratin 19 - - - - -23.4 
This table summarizes the proteomic and genetic changes associated with long- and 
short-term ketamine exposure. ATP = adenosine triphosphate; IL = interleukin, SD = 
Sprague-Dawley, TLR = toll-like receptor. Information taken from Ref. 260 (Shen et al., 






KETAMINE-INDUCED CYSTITIS: A NOVEL MECHANISTIC APPROACH 
 Ketamine-induced cystitis made its first clinical appearance in 2007 and was 
defined by the conserved gross pathologies and LUTS affecting patients with a 
long history of superfluous ketamine use. Although the clinical definition of KIC 
was of initial diagnostic and slight therapeutic use, it has since retarded efforts to 
fully understand its mechanism. Confined by ethical considerations and the illicit 
drug status of ketamine, human KIC studies harvested and analyzed the 
pathologic response in late-stage ketamine abusers who pursued treatment years 
after initial symptoms. Researchers succeeded in reproducing these findings in 
animal models by treating mice and rats with ketamine concentrations rivaling 
those of abusers over a period of 2–3 months, but this has left much uncertainty 
regarding the dose-dependent effects and long-term safety of ketamine use. 
Similar to human studies, animal tissue is typically extracted after the full time 
course of the experiment, creating significant lag time between the initial detection 
of cystometric and voiding spot assay (VSA) abnormalities and the actual 
investigation. As a result, most present research regarding the mechanism of KIC 
is confounded by superimposed acute and chronic inflammatory responses. This 
would explain some of the wide variation in observed pathology, including 
sloughing off and ulceration of the urothelium, intense eosinophilic infiltrates, 




 Current research in KIC has failed to address many of the questions 
surrounding the reported dose-dependent toxicity of ketamine. This dose-
dependent profile has been well established in embryonic stem cell-derived 
neuronal cell cultures by Bosnjak et al. In their study, ketamine elicited significant 
reductions in cell viability at concentrations above 2500 µM but was benign in the 
reported range of anesthetic levels (10–20 µM).262 The same profile was found in 
studies of bladder cells, as ketamine appeared to be cytotoxic at levels associated 
with abuse.192,224 Cell culture, by its nature, is a strong tool for examining dose-
dependent effects but has implicit limitations in evaluating change with respect to 
duration. To address time-dependent effects of ketamine, animal models were 
subjected to a course of daily ketamine treatment at levels reported in abuse. At 
≥30 mg/kg/day, ketamine significantly increased levels of apoptosis in bladder 
samples taken from animal models of KIC over time courses ranging from 2 to 3 
months. Although this result corroborates the proposed urological toxicity of 
ketamine, it did so only at levels associated with abuse.263 As of this paper, there 
has yet to be a study investigating the long-term urological consequences of 
ketamine at anesthetic, pain-management, or antidepressant doses.  
It is hard to argue that aspects of KIC are not mediated by direct cytotoxicity, 
but occasionally the hallmark signs of urothelial denudation and intense 
inflammatory infiltration are absent despite voiding dysfunction and LUTS. The 
liver rapidly metabolizes ketamine, making it undetectable in serum roughly 8-10 




occur as ketamine and its metabolites collect in the urine. This would suggest an 
initial insult that begins at the urothelium and progressively implicates additional 
tissue layers, but the urothelial barrier function remains intact in some cases 
despite treatment with “cytotoxic” 30 mg/kg/day ketamine. In many animal studies, 
voiding dysfunction was detected well before any observable changes in histology. 
Therefore, it is more likely that ketamine-induced apoptosis represents a transition 
point between reversible, signaling dysfunction and irreversible, gross pathology. 
Following the onset of voiding dysfunction, the KIC bladder undergoes 
pathophysiological adaptations as it attempts to compensate for extreme 
demands. This series of pathophysiological adaptations has been well 
characterized in other benign bladder disorders, such as chronic outlet obstruction 
and denervation, and includes increased fibrosis, muscle hypertrophy, and 
microvascular changes.94 Despite intensifying voiding issues and continued 
ketamine use, the urothelium remains intact, preventing the drug and other 
metabolites in urine from promoting apoptosis and inflammation within 
submucosa. However, it is theoretically possible that ketamine is directly cytotoxic 
to the urothelium, but when considering the absence of epithelial damage reported 
in some KIC studies, it appears more likely that the urothelium exhausts its 
adaptive capacity, or suffers signaling dysregulation, that compromises 
permeability and facilitates the apoptotic and chronic inflammatory reactions 




Urothelial damage and altered barrier function have been reported in other 
benign bladder syndromes such as hemorrhagic cystitis, urinary tract infections, 
and denervation injury. In a rat model of spinal cord injuries, Apodaca et al. 
demonstrated significant alterations in urothelial permeability within 2 hours of 
injury. One day after the lesions, urotheliums evinced dramatically reduced 
transepithelial resistance and increased urea permeability that corresponded to 
umbrella cell loss and early signs of ulceration upon histological examination. By 
the fourth day, most SCI rats displayed a form of hemorrhagic cystitis resulting 
from submucosal exposure to urine.138 In the context of KIC, these findings 
buttress a two-stage mechanism of pathology that commences with dysregulated 
voiding and storage and culminates in the disruption of the urothelial barrier which 
enables the apoptotic and inflammatory responses associated with KIC. Overall, 
high doses of ketamine are cytotoxic, but the magnitude of this toxicity and its 
contribution to the KIC pathology are unclear. Urine can prompt comparable levels 
of inflammation and apoptosis following barrier disruption in other benign bladder 
disorders. Its contribution further complicates efforts to assess the role of urine 
ketamine in KIC and underscores the pressing need for research that fully 
addresses the safety of therapeutic doses.204 
 Voiding abnormalities have been reported as early as four weeks after 
ketamine exposure, but whether this is a direct effect of ketamine or a result of 
arbitrary timing of the initial measurement remains unclear.264 Nerve hyperplasia, 




dysfunction and recalcitrant pelvic pain observed in humans and animal models of 
KIC. In the CNS, the ability of ketamine to antagonize NMDA receptors has been 
well documented because the drug received FDA approval for its rapid 
upregulation of neurogenesis and synaptogenesis that can dramatically improve 
depressive symptoms. Thus, it was reasonable to assume that the same 
mechanism was afoot in ketamine-induced peripheral nerve hyperplasia. As of the 
writing of this paper, there is little evidence of NMDAR expression in the lower 
urinary tract apart from the scant levels found in the microvascular endothelial 
cells. Furthermore, the rapid filtration of ketamine and its metabolites by the 
kidneys allows little time for a direct interaction between ketamine and peripheral 
neurons. The evidence would then suggest that the onset of LUTs likely occurs as 
a consequence of NMDAR-mediated upregulation of neurotrophic factors in the 
CNS by ketamine. Proteins like BDNF, NGF, and GDNF spill over into the 
peripheral blood supply and then bind to their ubiquitously expressed receptors 
throughout the peripheral nervous system. The half-lives of these neurotrophic 
factors are significantly longer than the half-life of ketamine, and their serum levels 
increase nearly two-fold during ketamine treatment, facilitating their role in 
peripheral nerve hyperplasia and the development of LUTS.  
 In other benign bladder disorders, like IC or denervation, elevated levels of 
NGF in both serum and urine contribute to significant voiding dysfunction and 
urothelial apoptosis.265–267 An established focus in the treatment of these 
disorders, anti-NGF antibodies normalize urethral pressure during voiding in 
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models of SCI and attenuate voiding frequency and non-voiding contractions in 
models of cyclophosphamide-induced cystitis.268,269 When compared with NGF, 
levels of BDNF are a more sensitive and specific indicator of bladder overactivity. 
In addition, anti-BDNF antibody treatment significantly improved voiding efficiency 
in a mouse model of SCI.270  Neurotrophic factors can bind the p75 receptor and 
selectively promote apoptotic or survival responses, which may explain the 
differential rates of apoptosis seen in many KIC studies.271 Though paracrine in 
nature, ketamine prompts significant serum elevation of these factors which are 
capable of diffusing about 3 mm.272,273 Neurotrophic factors could potentially alter 
bladder signaling, centrally and peripherally, eliciting LUTS and an erosion of 
bladder function.  
Proteomic analyses of KIC biopsies demonstrate altered expression of β3-
adrenergic, M3 muscarinic, and purinergic receptors. These signaling pathways 
are critical for normal bladder function, controlling relaxation, contraction, and 
sensory transduction, respectively. The dysregulation of these mechanisms is 
sufficient to dramatically alter voiding dynamics. Upregulated nerve growth factors 
hypersensitize afferent nerve endings within the bladder. In the detrusor this could 
explain reduced bladder capacity by increasing afferent feedback, resulting in 
overestimation of bladder capacity by the pontine storage and micturition center 
and altered voiding patterns. Altered expression of β3-adrenergic and M3 
muscarinic receptors, which regulate relaxation and contraction, respectively, 
would serve as an additional source of altered voiding characteristics. In the 
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mucosa and submucosa, nerve hyperplasia and hypertrophy would augment the 
nociception arising from downstream inflammatory responses contributing to 
intractable pain. Increased purinergic signaling has been implicated as a major 
source of neuropathic pain following neuronal insult and would explain the 
recalcitrance of pelvic pain despite anti-inflammatories, such as NSAIDs or 
steroids. Taken as a whole, ketamine-induced neurotrophic factor upregulation 
may represent the initial instigator of LUTS in KIC that sets the stage for urothelial 
barrier disruption and the significant chronic inflammatory response associated 
with late-stage KIC. 
Significant questions remain about the dose-dependent effects of ketamine 
on voiding dysfunction and the long-term safety of the drug that warrant the 
attention of research efforts going forward. Investigations of therapeutic dosages 
of ketamine may yield valuable information for clinicians, though it will be limited 
by current models. To localize the effects of ketamine on the lower urinary tract, 
delivery methods should be varied beyond the traditional IP injection, incorporating 
intravesicular, intrathecal, and subcutaneous approaches. The contribution of 
urine ketamine can be assessed by establishing a baseline disruption of barrier 
function, potentially following SCI before these animals receive intravesicular 
ketamine or saline. With a serious need for an effective treatment, there is much 
to be discovered about KIC. Coadministration of anti-NGF antibodies may 
represent a viable long-term treatment strategy, but experiments have yet to 
evaluate the role of NGF in KIC.  
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